(FILE 'HOME' ENTERED AT 11:04:48 ON 30 MAR 2001)

FILE 'REGISTRY' ENTERED AT 11:04:57 ON 30 MAR 2001
L1 18 S YLTKEECLKK/SQSP
L2 23 S CTANAVTGPC/SQSP

FILE 'CA' ENTERED AT 11:06:06 ON 30 MAR 2001
L3 7 S L1
L4 8 S L2
L5 1 S L4 NOT L3
L6 0 S MONOKUNIN
L7 1412 S KUNITZ
L8 4 S L3 AND L7
L9 161 S BIKUNIN
L10 27 S L7 AND L9
L11 42 S KUNIN
L12 0 S L11 AND L7
L13 0 S L9 AND L11
L14 287 S URINARY TRYPSIN INHIBITOR OR HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR
L15 0 S L14 AND L11
L16 32 S L7 AND L14
L17 422 S L9 OR L14 OR L4
L18 154189 S DOMAIN
L19 53 S L17 AND L18

L5 ANSWER 1 OF 1 CA COPYRIGHT 2001 ACS
AN 129:171519 CA
TI Tissue factor pathway inhibitor-3
IN Gentz, Reiner L.; Hsu, Tsu-An; Ni, Jian; Rosen, Craig A.
PA Human Genome Sciences, Inc., USA
SO PCT Int. Appl., 58 pp. CODEN: PIXXD2 DT Patent LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 9833920 A2 19980806 WO 1998-US1468 19980127
WO 9833920 A3 19981105
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
AU 9860422 A1 19980825 AU 1998-60422 19980127
EP 1005551 A2 20000607 EP 1998-903730 19980127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
PRAI US 1997-36703 19970131 WO 1998-US1468 19980127
AB The present invention relates to a novel human TFPI-3 protein which is a member of the tissue factor protease inhibitor family. TFPI-3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TFPI-3 activity. Also provided are diagnostic methods for detecting hemostasis system-related disorders and therapeutic methods for treating hemostatis system-related disorders.

L3 ANSWER 1 OF 7 CA COPYRIGHT 2001 ACS
TI Human cancer-associated gene sequences and polypeptides PY 2000

L3 ANSWER 2 OF 7 CA COPYRIGHT 2001 ACS
TI Kunitz-type serine proteinase inhibitors for accelerating the rate of mucociliary clearance PY 2000

2000

L3 ANSWER 3 OF 7 CA COPYRIGHT 2001 ACS
TI Cloning of a new Kunitz-type protease inhibitor with a putative transmembrane domain overexpressed in pancreatic cancer PY 1998

L3 ANSWER 4 OF 7 CA COPYRIGHT 2001 ACS AN 128:58891 CA
TI Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor
AU Kawaguchi, Toshiya; Qin, Li; Shimomura, Takeshi; Kondo, Jun; Matsumoto, Kouji; Denda, Kimitoshi; Kitamura, Naomi
CS Research Center, Mitsubishi Chemical Corp., Yokohama, 227, Japan
SO J. Biol. Chem. (1997), 272(44), 27558-27564 CODEN: JBCHA3; ISSN: 0021-9258 PB American Society for Biochemistry and Molecular Biology DT Journal LA English

L3 ANSWER 5 OF 7 CA COPYRIGHT 2001 ACS AN 127:289126 CA
TI Production of functionally active recombinant human bikunin and fragments, blood plasma kallikrein inhibition, and pharmaceutical uses
IN Tamburini, Paul P.; Davis, Gary; Delaria, Katherine A.; Marlor, Christopher W.; Muller, Daniel K.
PA Bayer Corporation, USA; Tamburini, Paul P.; Davis, Gary; Delaria, Katherine A.; Marlor, Christopher W.; Muller, Daniel K.
SO PCT Int. Appl., 110 pp. CODEN: PIXXD2 DT Patent LA English FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 9733996 A2 19970918 WO 1997-US3894 19970310
WO 9733996 A3 19971113
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, US, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
CA 2247888 AA 19970918 CA 1997-2247888 19970310
AU 9722077 A1 19971001 AU 1997-22077 19970310
AU 716923 B2 20000309
EP 891426 A2 19990120 EP 1997-915029 19970310
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
BR 9708021 A 19990727 BR 1997-8021 19970310
CN 1259999 A 20000712 CN 1997-194556 19970310
ZA 9702084 A 19980911 ZA 1997-2084 19970311
PRAI US 1996-13106 19960311 US 1996-19793 19960614 US 1996-725251 19961004 WO 1997-US3894 19970310

L3 ANSWER 6 OF 7 CA COPYRIGHT 2001 ACS
TI Identification and cloning of human placental bikunin, a novel serine protease inhibitor containing two Kunitz dor
PY 1997

L3 ANSWER 7 OF 7 CA COPYRIGHT 2001 ACS AN 126:207827 CA
TI An inhibitor of hepatocyte growth factor activator proteinase activity and a cDNA encoding it and their uses
IN Shimomura, Takeshi; Kawaguchi, Toshiya; Kitamura, Naomi
PA Mitsubishi Chemical Corporation, Japan
SO Eur. Pat. Appl., 24 pp. CODEN: EPXXDW DT Patent LA English FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI EP 758682 A2 19970219 EP 1996-111861 19960723
EP 758682 A3 19971112
R: DE, FR, GB
JP 09095498 A2 19970408 JP 1996-193584 19960723
US 5731412 A 19980324 US 1996-685660 19960724
US 5854396 A 19981229 US 1997-974196 19971119
PRAI JP 1995-187134 19950724 US 1996-685660 19960724

L8 ANSWER 1 OF 4 CA COPYRIGHT 2001 ACS

TI *Kunitz*-type serine proteinase inhibitors for accelerating the rate of mucociliary clearance

L8 ANSWER 2 OF 4 CA COPYRIGHT 2001 ACS
TI Cloning of a new *Kunitz*-type protease inhibitor with a putative transmembrane domain overexpressed in pancreatic cancer

L8 ANSWER 3 OF 4 CA COPYRIGHT 2001 ACS
TI Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a *Kunitz*-type serine protease inhibitor

L8 ANSWER 4 OF 4 CA COPYRIGHT 2001 ACS
TI Identification and cloning of human placental bikunin, a novel serine protease inhibitor containing two*Kunitz*domains

L10 ANSWER 1 OF 27 CA COPYRIGHT 2001 ACS
TI Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironmentPY 2000

L10 ANSWER 2 OF 27 CA COPYRIGHT 2001 ACS
TI α1-Microglobulin: a yellow-brown lipocalin PY 2000

L10 ANSWER 3 OF 27 CA COPYRIGHT 2001 ACS
TI Suppression of urokinase-type plasminogen activator expression from human ovarian cancer cells by urinary trypsin inhibitor PY 2000

L10 ANSWER 4 OF 27 CA COPYRIGHT 2001 ACS
TI Genomic structure and chromosomal localization of the human hepatocyte growth factor activator inhibitor type 1 and 2 genes PY 2000

L10 ANSWER 5 OF 27 CA COPYRIGHT 2001 ACS AN 133:84295 CA
TI *Kunitz*-type serine proteinase inhibitors for accelerating the rate of mucociliary clearance
IN Hall, Roderick; Poll, Christopher T.; Newton, Benjamin B.; Taylor, William J. A.
PA Bayer Aktiengesellschaft, Germany
SO PCT Int. Appl., 173 pp. CODEN: PIXXD2 DT Patent LA English FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2000037099 A2 20000629 WO 1999-GB4381 19991222
WO 2000037099 A3 20001026
W: AE, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, CZ, DE, DE, DK, DK, DM, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRAI US 1998-218913 19981222 US 1999-441966 19991117

L10 ANSWER 6 OF 27 CA COPYRIGHT 2001 ACS
TI Proteoglycan core protein in human urine and its possible role on calcium oxalate urolithiasisPY 1999

L10 ANSWER 7 OF 27 CA COPYRIGHT 2001 ACS
TI Generation of catalytically active granzyme K from Escherichia coli inclusion bodies and identification of efficient granzyme K inhibitors in human plasma PY 1999

L10 ANSWER 8 OF 27 CA COPYRIGHT 2001 ACS
TI Urinary trypsin inhibitor down-regulates hyaluronic acid fragment-induced prostanoid release in cultured human amnion cells by inhibiting cyclo-oxygenase-2 expression PY 1999

L10 ANSWER 9 OF 27 CA COPYRIGHT 2001 ACS
TI Detection of *bikunin* mRNA in limited portions of rat brain PY 1999

L10 ANSWER 10 OF 27 CA COPYRIGHT 2001 ACS
TI Temporal changes in mRNA expression for *bikunin* in the kidneys of rats during calcium oxalate nephrolithiasis PY 1999

L10 ANSWER 11 OF 27 CA COPYRIGHT 2001 ACS
TI Guinea pig α1-microglobulin/ *bikunin*: cDNA sequencing, tissue expression and expression during acute phase PY 1999

L10 ANSWER 12 OF 27 CA COPYRIGHT 2001 ACS AN 130:207692 CA
TI Assembly and secretion of recombinant chains of human inter-α- trypsin inhibitor in COS-7 cells
AU Martin-Vandelet, Nathalie; Paris, Sebastien; Bourguignon, Jeannette; Sesboue, Richard; Martin, Jean-Pierre; Diarra-Mehrpour, Maryam
CS Laboratoire de Physiopathologie et Genetique Renale et Pulmonaire, Institut National de la Sante et de la Recherche Medicale, INSERM Unite 295, Faculte de Medecine de Rouen, and IFR 61: phy, Rouen, F-76183, Fr.
SO Eur. J. Biochem. (1999), 259(1/2), 476-484 CODEN: EJBCAI; ISSN: 0014-2956 PB Blackwell Science Ltd. DT Journal LA English
AB The inter-α-trypsin inhibitor (ITI) family is a group of structurally related plasma serine protease inhibitors. The ITI family members consist of combinations of mature heavy chains named HC1, HC2, HC3 linked to *bikunin* (a *Kunitz*-type protease inhibitor) by a covalent interchain protein-glycosaminoglycan-protein cross-link. The biosynthesis of the ITI family members takes place in the liver. In this report we examine the biosynthesis of these proteins using transient transfected COS-7 cells expressing one or more combinations of human ITI chains. The processing and secretion of α1-microglobulin and *bikunin* does not require the ITI heavy chains. A small proportion of the H3 chain seems to be processed into the HC3 form in the absence of the other ITI chains. In contrast, the processing of H2 into HC2 needs the presence of the L chain. The COS-7 cells are able to link the HC2 and HC3 heavy chains with *bikunin* by means of a chondroitin sulfate bridge, and thus to generate 260-kDa ITI-like proteins as well as pre-α-trypsin inhibitor (Pαl). However, the maturation of the H1 chain into HC1 and the assembly of HC1 inside multichain proteins may take place according to a mechanism which differs from that of the H2 and H3 chains. These results indicate that the assembly of the constituent chains of the ITI-like proteins and Pαl is not dependent on the liver machinery.
RE.CNT 31 RE
(1) Balduyck, M; Biol Chem Hoppe Seyler 1989, V370, P329 CA
(2) Blom, A; Biochem J 1997, V328, P185 CA
(3) Bost, F; Eur J Biochem 1998, V252, P339 CA
(4) Bourguignon, J; Biochem J 1989, V261, P305 CA
(5) Bourguignon, J; Eur J Biochem 1993, V212, P771 CA
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 13 OF 27 CA COPYRIGHT 2001 ACS AN 129:2052 CA
TI The crystal structure of *Bikunin* from the inter-α- inhibitor complex: a serine protease inhibitor with two *Kunitz* domains
AU Xu, Yibin; Carr, Paul D.; Guss, J. Mitchell; Ollis, David L.
CS Research School of Chemistry, Australian National University, Canberra, ACT 2601, Australia
SO J. Mol. Biol. (1998), 276(5), 955-966 CODEN: JMOBAK; ISSN: 0022-2836 PB Academic Press Ltd.
DT Journal LA English
AB *Bikunin* is a serine protease inhibitor found in the blood serum and urine of humans and other animals. Its sequence shows internal repetition, suggesting that it contains two domains that resemble bovine pancreatic trypsin inhibitor (BPTI). A fragment of *bikunin* has been crystd., its structure solved and subsequently refined against 2.5 .ANG. data. The two BPTI-like domains pack closely together and are related by an approx. 60.degree. rotation combined with a translation. These domains are very similar to each other and other proteins with this fold. The largest variations occur in the loops responsible for protease recognition. The loops of the first domain are unobstructed by the remaining protein. However, the loops of the second domain are close to the first domain and it is possible that protease binding m[illegible] be affected or, in some cases, abolished by the presence of the first domain. Thus, cleavage of the tw[illegible] domains could alter the substrate pecificity of domain II. *Bikunin* has a hydrophobic patch close to the N terminus of domain I, which is the most likely site for cell-surface receptor binding. In addn., there is a basic patch at one end of domain II that may be responsible for the inhibition of calcium oxalate crystn. in urine.

L10 ANSWER 14 OF 27 CA COPYRIGHT 2001 ACS
TI Inhibition of tryptase TL2 from human T4+ lymphocytes and inhibition of HIV-1 replication in H9 cells by recombinant aprotinin and *bikunin* homologs PY 1997

L10 ANSWER 15 OF 27 CA COPYRIGHT 2001 ACS
TI Recombinant preparation in Pichia of human protease inhibitor mutants with improved activity on inhibiting neutrophil elastase PY 1997

L10 ANSWER 16 OF 27 CA COPYRIGHT 2001 ACS
TI Identification and cloning of human placental *bikunin*, a novel serine protease inhibitor containing two *Kunitz*domains PY 1997

L10 ANSWER 17 OF 27 CA COPYRIGHT 2001 ACS
TI Characterization of placental *bikunin*, a novel human serine protease inhibitor PY 1997

L10 ANSWER 18 OF 27 CA COPYRIGHT 2001 ACS
TI Strong crossreaction of human anti-aprotinin antibodies from heart transplant patient with [Arg15]aprotinin PY 1997

L10 ANSWER 19 OF 27 CA COPYRIGHT 2001 ACS
TI Human urinary trypsin inhibitor and fragments and their recombinant preparation with Pichia PY 1996

L10 ANSWER 20 OF 27 CA COPYRIGHT 2001 ACS
TI Sequence analysis and evolutionary aspects of piscine α-1- microglobulin/ *bikunin* mRNA transcripts PY 1995

L10 ANSWER 21 OF 27 CA COPYRIGHT 2001 ACS
TI Isolation and characterization of novel blood coagulation factor Xa (FXa) inhibitor (R-020) and its variants PY 1994

L10 ANSWER 22 OF 27 CA COPYRIGHT 2001 ACS
TI Sequencing of cDNAs encoding α1-microglobulin/ *bikunin* of Mongolian gerbil and Syrian golden hamster in omparison with man and other species PY 1994

L10 ANSWER 23 OF 27 CA COPYRIGHT 2001 ACS
TI Developmentally regulated transcription of the four liver-specific genes for inter-α-inhibitor family in mouse PY 1993

L10 ANSWER 24 OF 27 CA COPYRIGHT 2001 ACS
TI Mouse α-1-microglobulin/ *bikunin* precursor: cDNA analysis, gene evolution and physical assignment of the gene next to the orosomucoid locus PY 1993

L10 ANSWER 25 OF 27 CA COPYRIGHT 2001 ACS
TI Homologous chromosomal locations of the four genes for inter-α-inhibitor and pre-α-inhibitor family in human and mouse: assignment of the ancestral gene for the lipocalin superfamily PY 1992

L10 ANSWER 26 OF 27 CA COPYRIGHT 2001 ACS AN 115:107384 CA
TI Structure of the human α1-microglobulin- *bikunin* gene
AU Vetr, Helga; Gebhard, Wolfgang
CS Klin. Grosshadern, Ludwig-Maximilians-Univ., Munich, W-8000/70, Fed. Rep. Ger.
SO Biol. Chem. Hoppe-Seyler (1990), 371(12), 1185-96 CODEN: BCHSEI; ISSN: 0177-3593 DT Journal
LA English
AB α1-Microglobulin (protein HC) and *bikunin* (formerly HI-30, urinary trypsin inhibitor, inhibitor subunit of inter-α-(trypsin) inhibitor) are abundant serum glycoproteins. They belong to 2 distinct protein families, the lipocalin family, a family of transport proteins for small hydrophobic mols. and the *Kunitz*-family of proteinase inhibitors. Mature α1-microglobulin and *bikunin* result from a common precursor. The human gene coding for this precursor protein was isolated and sequenced. The gene consists of 10 exons which span 1.3 kb and 9 introns with an aggregate length of about 16.5 kb. The largest intron (6.5 kb) separates exon 6 (coding for the C-terminal sequence of α1-microglobulin) from exon 7 (coding for a linker peptide and the N-terminal peptide of *bikunin*). Repetitive DNA sequences of the Alu-type occur downstream of the polyadenylation site, within introns 4 and 6, and upstream of the putative promoter region which has been defined by sequence comparison and transcription start site detn. The gene also contains several sequence motifs reminiscent to known enhancer sequences.

L10 ANSWER 27 OF 27 CA COPYRIGHT 2001 ACS
TI Structure of inter-α-inhibitor (inter-α-trypsin inhibitor) and pre-α-inhibitor: current state and proposition of a new terminologyPY 1990

L16 ANSWER 1 OF 32 CA COPYRIGHT 2001 ACS
TI *Hepatocyte**growth**factor**activator**inhibitor* type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment PY 2000

L16 ANSWER 2 OF 32 CA COPYRIGHT 2001 ACS
TI Localization of *hepatocyte**growth**factor**activator**inhibitor* type 1 in Langhans' cells of human placenta PY 2000

L16 ANSWER 3 OF 32 CA COPYRIGHT 2001 ACS
TI Suppression of urokinase-type plasminogen activator expression from human ovarian cancer cells by *urinary**trypsin**inhibitor*PY 2000

L16 ANSWER 4 OF 32 CA COPYRIGHT 2001 ACS
TI Identification and characterization of a *Kunitz*-type protease inhibitor in ascites fluid from patients with ovarian carcinoma PY 2000

L16 ANSWER 5 OF 32 CA COPYRIGHT 2001 ACS
TI Genomic structure and chromosomal localization of the human *hepatocyte**growth**factor**activator**inhibitor* type 1 and 2 genes PY 2000

L16 ANSWER 6 OF 32 CA COPYRIGHT 2001 ACS
TI Identity of *urinary**trypsin**inhibitor* -binding protein to link protein PY 2000

L16 ANSWER 7 OF 32 CA COPYRIGHT 2001 ACS
TI Upregulation of HGF activator inhibitor type 1 but not type 2 along with regeneration of intestinal mucosa PY 2000

L16 ANSWER 8 OF 32 CA COPYRIGHT 2001 ACS
TI Multiple sites of proteolytic cleavage to release soluble forms of *hepatocyte**growth**factor**activator**inhibitor* type 1 from a transmembrane form PY 1999

L16 ANSWER 9 OF 32 CA COPYRIGHT 2001 ACS
TI *Urinary**trypsin**inhibitor* down-regulates hyaluronic acid fragment-induced prostanoid release in cultured human amnion cells by inhibiting cyclo-oxygenase-2 expression PY 1999

L16 ANSWER 10 OF 32 CA COPYRIGHT 2001 ACS AN 130:334283 CA
TI *Hepatocyte**Growth**Factor**Activator**Inhibitor* Type 2 Lacking the First *Kunitz*-Type Serine Proteinase Inhibitor Domain Is a Predominant Product in Mouse but Not in Human
AU Itoh, Hiroshi; Kataoka, Hiroaki; Hamasuna, Ryoichi; Kitamura, Naomi; Koono, Masashi
CS Second Department of Pathology, Miyazaki Medical College, Kiyotake, Miyazaki, 889-1692, Japan
SO Biochem. Biophys. Res. Commun. (1999), 255(3), 740-748 CODEN: BBRCA9; ISSN: 0006-291X PB Academic Press DT Journal LA English
AB *Hepatocyte**growth**factor**activator**inhibitor* type 2 (HAI-2) is a new *Kunitz*-type serine protease inhibitor, which is purified and cloned from human stomach cancer cell line MKN45. The mature HAI-2 protein contains two *Kunitz* domains and the first domain is mainly responsible for the inhibitory activity against hepatocyte growth factor activator (HGFA). In this study, we identified the mouse homolog of HAI-2 (mHAI-2) by screening the data base of public expressed sequence tag (dbEST). In addn. to a full-length cDNA corresponding to human HAI-2, a shorter size of mHAI-2 cDNA was obtained from mouse kidney by reverse-transcription polymerase chain reaction (RT-PCR). Sequence anal. of this shorter cDNA revealed that the region encoding the first *Kunitz* domain was completely deleted. Anal. of mouse genomic DNA showed that the deleted cDNA was generated by an alternative splicing mechanism. Surprisingly, the spliced form lacking the first *Kunitz* domain was a predominant transcript in all tissues of mice tested but not in those of human as assessed by RT-PCR anal. This phenomenon is also confirmed by Western blot anal. using the specific antiserum against human HAI-2 protein. These results suggest that most of HAI-2 expressed in various tissues of mice may be unable to inhibit HGFA efficiently. (c) 1999 Academic Press.
RE.CNT 34 RE
(1) Chang, J; Thromb Haemost 1998, V79, P306 CA
(2) Chu, M; EMBO J 1990, V9, P385 CA
(3) Delaria, K; J Biol Chem 1997, V272, P12209 CA
(4) Diarra-Mehrpour, M; Eur J Biochem 1990, V191, P131 CA
(5) Gebhard, W; Proteinase Inhibitors 1986, P375 CA
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 11 OF 32 CA COPYRIGHT 2001 ACS
TI White matter astrocytes produce *hepatocyte**growth**factor**activator**inhibitor* in human brain tissues PY 1998

L16 ANSWER 12 OF 32 CA COPYRIGHT 2001 ACS AN 130:11863 CA
TI Functional characterization of *Kunitz* domains in *hepatocyte**growth**factor**activator**inhibitor* type 2
AU Qin, Li; Denda, Kimitoshi; Shimomura, Takeshi; Kawaguchi, Toshiya; Kitamura, Naomi
CS Faculty of Bioscience and Biotechnology, Department of Life Science, Tokyo Institute of Technology, Yokohama, 226, Japan
SO FEBS Lett. (1998), 436(1), 111-114 CODEN: FEBLAL; ISSN: 0014-5793 PB Elsevier Science B.V.
DT Journal LA English
AB *Hepatocyte**growth**factor**activator**inhibitor* type 2 (HAI-2) was identified as a potent inhibitor of hepatocyte growth factor activator (HGF activator). The primary translation product of HAI-2 contains two *Kunitz* domains. To characterize their function, we introduced a point mutation into the reactive site of each *Kunitz* domain, and assayed the mutants for their HGF activator inhibitory activity. A point mutation in the COOH-terminal *Kunitz* domain did not affect the activity of HAI-2, whereas a point mutation in the NH2-terminal *Kunitz* domain markedly reduced the activity. These results suggest that the NH2-terminal *Kunitz* domain is mainly responsible for the HGF activator inhibitory activity of HAI-2.
RE.CNT 21 RE
(1) Delaria, K; J Biol Chem 1997, V272, P12209 CA
(2) Derijard, B; Cell 1994, V76, P1025 CA

(3) Girard, T; Nature 1989, V338, P518 CA
(4) Gohda, E; J Clin Invest 1988, V81, P414 CA
(5) Igawa, T; Biochem Biophys Res Commun 1991, V174, P831 CA
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 13 OF 32 CA COPYRIGHT 2001 ACS
TI *Urinary**trypsin**inhibitor* reduces the release of histamine from rat peritoneal mast cells PY 1998

L16 ANSWER 14 OF 32 CA COPYRIGHT 2001 ACS
TI Evaluation of *hepatocyte**growth**factor**activator**inhibitor* expression in normal and malignant colonic mucosa PY 1998

L16 ANSWER 15 OF 32 CA COPYRIGHT 2001 ACS
TI Role of O-linked carbohydrate of human *urinary**trypsin**inhibitor* on its lysosomal membrane-stabilizing property PY 1998

L16 ANSWER 16 OF 32 CA COPYRIGHT 2001 ACS
TI *Urinary**trypsin**inhibitor*, a *Kunitz* -type protease inhibitor, modulates tumor necrosis factor-stimulated activation and translocation of protein kinase C in U937 cells PY 1998

L16 ANSWER 17 OF 32 CA COPYRIGHT 2001 ACS
TI Purification and cloning of *hepatocyte**growth**factor**activator**inhibitor* type 2, a *Kunitz*-type serine protease inhibitor PY 1997

L16 ANSWER 18 OF 32 CA COPYRIGHT 2001 ACS AN 127:216908 CA
TI Purification and characterization of a novel protease inhibitor specific to hepatocyte growth factor activator
AU Kawaguchi, Toshiya; Shimomura, Takeshi; Denda, Kimitoshi; Kitamura, Akiko; Kondo, Jun; Kito, Masahiro; Kagaya, Shinji; Qin, Li; Takata, Hiroyuki; Miyazawa, Keiji; Kitamura, Naomi
CS Yokohama Research Center, Mitsubishi Chemical Corporation, Yokohama, 227, Japan
SO Anim. Cell Technol.: Basic Appl. Aspects, Proc. Annu. Meet. Jpn. Assoc. Anim. Cell Technol., 8th (1997), Meeting Date 1995, 403-407. Editor(s): Funatsu, Kazumori; Shirai, Yoshihito; Matsushita, Taku. Publisher: Kluwer, Dordrecht, Neth. CODEN: 64WUA2 DT Conference LA English
AB *Hepatocyte**growth**factor**activator**inhibitor* (HAI) was purified from serum-free conditioned medium of a human stomach carcinoma cell line, and a partial amino acid sequence was detd. The sequence data revealed that HAI is a novel proteinase inhibitor which contains a *Kunitz*-type serine proteinase inhibitory domain. Purified HAI inhibited hepatocyte growth factor activator in a concn.-dependent manner, but had no significant effect on factor XIIa.

L16 ANSWER 19 OF 32 CA COPYRIGHT 2001 ACS
TI Novel protease inhibitory activities of the second domain of urinary trypsin inhibitory (R-020) and its effect on sepsis-induced organ injury in rat PY 1996

L16 ANSWER 20 OF 32 CA COPYRIGHT 2001 ACS
TI Recombinant preparation in Pichia of human protease inhibitor mutants with improved activity on inhibiting neutrophil elastase PY 1997

L16 ANSWER 21 OF 32 CA COPYRIGHT 2001 ACS
TI *Hepatocyte**growth**factor**activator**inhibitor*, a novel *Kunitz*-type serine protease inhibitor PY 1997

L16 ANSWER 22 OF 32 CA COPYRIGHT 2001 ACS AN 124:336669 CA
TI Human *urinary**trypsin**inhibitor* and fragments and their recombinant preparation with Pichia
IN Ideno, Shoji; Goto, Takashi; Horii, Hajime
PA Green Cross Corporation, Japan
SO PCT Int. Appl., 97 pp. CODEN: PIXXD2 DT Patent LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9603503	A1	19960208	WO 1995-JP1449	19950721

W: CA, CN, JP, KR, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
PRAI JP 1994-169221 19940721
AB A process for producing a urinary human trypsin inhibitor (UTI) and domains thereof by using a yeast of the genus Pichia is described. The method involves the construction of expression plasmid contg. AOX1 promoter and SUC2. Plasmid pHH313 encoding *Kunitz* type domain I with addnl. 21 amino acids at its N-terminus and plasmid pHH314 encoding *Kunitz* type domain II were prepd. and used for the transformation of Pichia strain GTS115. *Kunitz* type domain II purified from the culture supernatant exhibited significant trypsin-inhibitory activity, but little inhibition to human neutrophil elastase. Ep1-UTI, a UTI mutant having the active site MGMTS replaced with IAFFP, was also prepd. and its improved elastase-inhibitory activity demonstrated. Prepn. and characterization of mutant Ep1-d21 having its N-terminal 21 amino acids deleted were also shown. The methods of this invention can be optimized for mass prodn. of UTI for use as therapeutics.

L16 ANSWER 23 OF 32 CA COPYRIGHT 2001 ACS
TI *Kunitz*-type trypsin inhibitor prevents LPS-induced increase of cytosolic free Ca2+ in human neutrophils and HUVEC cells PY 1995

L16 ANSWER 24 OF 32 CA COPYRIGHT 2001 ACS
TI Isolation and characterization of novel blood coagulation factor Xa (FXa) inhibitor (R-020) and its variants PY 1994

L16 ANSWER 25 OF 32 CA COPYRIGHT 2001 ACS
TI Down-regulation of interleukin-8 gene expression in HL60 cell line by human *Kunitz*-type trypsin inhibitor PY 1995

L16 ANSWER 26 OF 32 CA COPYRIGHT 2001 ACS
TI Protective effect of recombinant neutrophil elastase inhibitor (R-020) on sepsis-induced organ injury in rat PY 1994

L16 ANSWER 27 OF 32 CA COPYRIGHT 2001 ACS AN 120:211333 CA
TI Novel factor Xa and plasma kallikrein inhibitory activities of the second *Kunitz*-type inhibitory domain of *urinary**trypsin**inhibitor*
AU Morishita, Hideaki; Yamakawa, Toru; Matsusue, Tomokazu; Kusuyama, Takeshi; Sameshima-Aruga, Rie; Hirose, Jiro; Nii, Atsushi; Miura, Toshihisa; Isaji, Mitsuko; et al.
CS Biosci. Res. Lab., Mochida Pharm. Co. Ltd., Tokyo, 115, Japan
SO Thromb. Res. (1994), 73(3-4), 193-204 CODEN: THBRAA; ISSN: 0049-3848 DT Journal LA English
AB *Urinary**trypsin**inhibitor* is a glycoprotein with a structure in which 2 *Kunitz*-type inhibitory domains are linked in a row. Two genes were isolated encoding the 70-amino-acid sequence from the 78th amino acid (Thr) to the C-terminal and the 68-amino-acid sequence from the 80th (Ala) to C-terminal of human *urinary**trypsin**inhibitor*, both which correspond to the 2nd *Kunitz*-type inhibitory domain, and then expression plasmids were constructed by ligating it to the Echerichia coli alk. phosphatase signal peptide gene. These plasmids under the control of the tryptophan promoter expressed the 2nd domain in E. coli strain JE5505 which lacks the membrane lipoprotein. The recombinant 2nd domain purified from the culture supernatant of the transformant inhibited trypsin, plasmin, leukocyte elastase, and chymotrypsin which are known to be inhibited by *urinary**trypsin**inhibitor*. In addn. it inhibited blood coagulation factor Xa and plasma kallikrein in a concn.-dependent and competitive manner, and significantly prolonged the plasma-based activated partial thromboplastin time (APTT). The truncated natural counterpart obtained by a limited degrdn. of human *urinary**trypsin**inhibitor* revealed identical inhibitory activities.

L16 ANSWER 28 OF 32 CA COPYRIGHT 2001 ACS
TI Structure of the human α1-microglobulin-bikunin gene PY 1990

L16 ANSWER 29 OF 32 CA COPYRIGHT 2001 ACS
TI Structure of inter-α-inhibitor (inter-α-trypsin inhibitor) and pre-α-inhibitor: current state and proposition of a new terminology PY 1990

L16 ANSWER 30 OF 32 CA COPYRIGHT 2001 ACS
TI cDNA cloning of human inter-α-trypsin inhibitor discloses three different proteins PY 1987

L16 ANSWER 31 OF 32 CA COPYRIGHT 2001 ACS AN 96:48145 CA
TI *Kunitz*-type proteinase inhibitors derived by limited proteolysis of the inter-α-trypsin inhibitor. V. Attachments of carbohydrates in the human *urinary*trypsin*inhibitor* isolated by affinity chromatography
AU Hochstrasser, Karl; Schoenberger, Oeyvind L.; Rossmanith, Ingrid; Wachter, Elmar
CS Biochem. Labor Klin., Univ. Muenchen, Munich, Fed. Rep. Ger.
SO Hoppe-Seyler's Z. Physiol. Chem. (1981), 362(10), 1357-62 CODEN: HSZPAZ; ISSN: 0018-4888 DT Journal LA English
AB Trypsin inhibitor HI-30 of human urine, physiol. released from inter-α-trypsin inhibitor and having a known peptide sequence, was purified by affinity chromatog. and its carbohydrate structure was detd. The carbohydrates, which comprise .apprx.50 of the inhibitor, are attached to the peptide moiety at 2 sites. One chain is linked O-glycosidically via serine-10 in the N-terminal extension peptide and the other is linked N-glucosidically via arginine-24 in the inactive inhibitory *Kunitz* -type domain of the inhibitor. The complete sequences of the carbohydrate chains were detd.

L16 ANSWER 32 OF 32 CA COPYRIGHT 2001 ACS AN 96:48144 CA
TI *Kunitz*-type proteinase inhibitors derived by limited proteolysis of the inter-α-trypsin inhibitor. IV. The amino acid sequence of the human *urinary**trypsin**inhibitor* isolated by affinity chromatography
AU Wachter, Elmar; Hochstrasser, Karl
CS Inst. Physiol. Chem. Phys. Biochem. Zellbiol., Univ. Muenchen, Munich, Fed. Rep. Ger.
SO Hoppe-Seyler's Z. Physiol. Chem. (1981), 362(10), 1351-5 CODEN: HSZPAZ; ISSN: 0018-4888 DT Journal LA English
AB The amino acid sequence of the complete polypeptide chain of human *urinary**trypsin**inhibitor* HI-30, physiol. released from human inter-α-trypsin inhibitor and comprised of a C-terminal domain with antitrypsin activity and a domain displaying no inhibitory activity, was detd. Both the N-terminal extension peptide with 21 residues and the inactive domain are linked O- and N-glycosidically, resp., to large carbohydrate moieties. The N-terminal amino acid sequence of the inhibitor was detd. by solid-phase Edman degrdn. of a single peptide. The mol. wt. calcd. for the total polypeptide chain of 143 residues was 15,340. In consideration of the difference between this value and the exptl. detd. value (30,000), the glycopeptide evidently contains a carbohydrate moiety of considerable mol. wt.

L19 ANSWER 1 OF 53 CA COPYRIGHT 2001 ACS
TI *Hepatocyte**growth**factor**activator**inhibitor* type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment PY 2000

L19 ANSWER 2 OF 53 CA COPYRIGHT 2001 ACS
TI Method for identifying toxic agents in liver tissues using differential gene expression PY 2001

L19 ANSWER 3 OF 53 CA COPYRIGHT 2001 ACS
TI Identification and characterization of a Kunitz-type protease inhibitor in ascites fluid from patients with ovarian carcinoma PY 2000

L19 ANSWER 4 OF 53 CA COPYRIGHT 2001 ACS
TI Genomic structure and chromosomal localization of the human *hepatocyte**growth**factor**activator**inhibitor* type 1 and 2 genes PY 2000

L19 ANSWER 5 OF 53 CA COPYRIGHT 2001 ACS
TI Identity of *urinary**trypsin**inhibitor* -binding protein to link protein PY 2000

L19 ANSWER 6 OF 53 CA COPYRIGHT 2001 ACS
TI Upregulation of HGF activator inhibitor type 1 but not type 2 along with regeneration of intestinal mucosa PY 2000

L19 ANSWER 7 OF 53 CA COPYRIGHT 2001 ACS
TI Proteoglycan core protein in human urine and its possible role on calcium oxalate urolithiasis PY 1999

L19 ANSWER 8 OF 53 CA COPYRIGHT 2001 ACS
TI Multiple sites of proteolytic cleavage to release soluble forms of *hepatocyte**growth**factor**activator**inhibitor* type 1 from a transmembrane form PY 1999

L19 ANSWER 9 OF 53 CA COPYRIGHT 2001 ACS
TI Generation of catalytically active granzyme K from Escherichia coli inclusion bodies and identification of efficient granzyme K inhibitors in human plasma PY 1999

L19 ANSWER 10 OF 53 CA COPYRIGHT 2001 ACS
TI Expression vectors for eukaryotic cells that direct accurate splicing of primary transcripts PY 1999 1999 2000

L19 ANSWER 11 OF 53 CA COPYRIGHT 2001 ACS
TI Guinea pig α1-microglobulin/ *bikunin*: cDNA sequencing, tissue expression and expression during acute phase PY 1999

L19 ANSWER 12 OF 53 CA COPYRIGHT 2001 ACS
TI *Hepatocyte**Growth**Factor**Activator**Inhibitor* Type 2 Lacking the First Kunitz-Type Serine Proteinase Inhibitor *Domain* Is a Predominant Product in Mouse but Not in Human PY 1999

L19 ANSWER 13 OF 53 CA COPYRIGHT 2001 ACS
TI Structural characterization of inter-α-inhibitor. Evidence for an extended shape PY 1999

L19 ANSWER 14 OF 53 CA COPYRIGHT 2001 ACS
TI Fusion proteins of receptor ligand-binding domains and proteinase inhibitors for inhibition of cell migration PY 1998 1999 1998 2000 2000

L19 ANSWER 15 OF 53 CA COPYRIGHT 2001 ACS AN 130:11863 CA
TI Functional characterization of Kunitz domains in *hepatocyte**growth**factor**activator**inhibitor* type 2
AU Qin, Li; Denda, Kimitoshi; Shimomura, Takeshi; Kawaguchi, Toshiya; Kitamura, Naomi
CS Faculty of Bioscience and Biotechnology, Department of Life Science, Tokyo Institute of Technology, Yokohama, 226, Japan
SO FEBS Lett. (1998), 436(1), 111-114 CODEN: FEBLAL; ISSN: 0014-5793PB Elsevier Science B.V.
DT Journal LA English
AB *Hepatocyte**growth**factor**activator**inhibitor* type 2 (HAI-2) was identified as a potent inhibitor of hepatocyte growth factor activator (HGF activator). The primary translation product of HAI-2 contains two Kunitz domains. To characterize their function, we introduced a point mutation into the reactive site of each Kunitz *domain*, and assayed the mutants for their HGF activator inhibitory activity. A point mutation in the COOH-terminal Kunitz *domain* did not affect the activity of HAI-2, whereas a point mutation in the NH2-terminal Kunitz *domain* markedly reduced the activity. These results suggest that the NH2-terminal Kunitz *domain* is mainly responsible for the HGF activator inhibitory activity of HAI-2.
RE.CNT 21 RE
(1) Delaria, K; J Biol Chem 1997, V272, P12209 CA
(2) Derijard, B; Cell 1994, V76, P1025 CA
(3) Girard, T; Nature 1989, V338, P518 CA
(4) Gohda, E; J Clin Invest 1988, V81, P414 CA
(5) Igawa, T; Biochem Biophys Res Commun 1991, V174, P831 CA
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 16 OF 53 CA COPYRIGHT 2001 ACS AN 129:171519 CA
TI Tissue factor pathway inhibitor-3
IN Gentz, Reiner L.; Hsu, Tsu-An; Ni, Jian; Rosen, Craig A.
PA Human Genome Sciences, Inc., USA
SO PCT Int. Appl., 58 pp. CODEN: PIXXD2 DT Patent LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9833920	A2	19980806	WO 1998-US1468	19980127
WO 9833920	A3	19981105		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
AU 9860422 A1 19980825 AU 1998-60422 19980127
EP 1005551 A2 20000607 EP 1998-903730 19980127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
PRAI US 1997-36703 19970131 WO 1998-US1468 19980127
AB The present invention relates to a novel human TFPI-3 protein which is a member of the tissue factor protease inhibitor family. TFPI-3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TFPI-3 activity. Also provided are diagnostic methods for detecting hemostasis system-related disorders and therapeutic methods for treating hemostatis system-related disorders.

L19 ANSWER 17 OF 53 CA COPYRIGHT 2001 ACS
TI A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and *domain* II of *bikunin* efficiently inhibits tumor cell invasion and metastasis PY 1998

L19 ANSWER 18 OF 53 CA COPYRIGHT 2001 ACS AN 129:144599 CA
TI A bifunctional hybrid molecule of urokinase amino-terminal fragment and *bikunin**domain* II efficiently inhibits tumor cell invasion and metastasis
AU Kobayashi, H.; Terao, T.
CS Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, Shizuoka, 431-31, Japan
SO Int. Congr. Ser. (1997), 1129(Recent Progress in Blood Coagulation and Fibrinolysis), 249-252 CODEN: EXMDA4; ISSN: 0531-5131 PB Elsevier Science B.V. DT Journal LA English
AB *Urinary**trypsin**inhibitor* (UTI) efficiently inhibits tumor cell invasion and the formation of metastasis. The anti-metastatic effect is dependent on the COOH-terminal *domain*II of UTI (HI-8). In order to develop a mol. that binds with high affinity to the urokinase receptor (uPAR) on tumor cell

surface, a bifunctional hybrid mol. (ATFHI) consisting of the uPAR-binding amino-terminal fragment (ATF) of uPA (amino acid sequence 1-134) at the NH2-terminus of HI-8 was produced in Escherichia coli by protein engineering.

L19 ANSWER 19 OF 53 CA COPYRIGHT 2001 ACS
TI Identification of structural domains in inter-α-trypsin inhibitor involved in calcium oxalate crystallization PY 1998

L19 ANSWER 20 OF 53 CA COPYRIGHT 2001 ACS
TI Preparation and use of drugs containing phospholipid-targeting peptides PY 1998 1999

L19 ANSWER 21 OF 53 CA COPYRIGHT 2001 ACS
TI Internalization of *urinary**trypsin**inhibitor*in human uterine fibroblasts PY 1998

L19 ANSWER 22 OF 53 CA COPYRIGHT 2001 ACS
TI Identification and characterization of the cell-associated binding protein for *urinary**trypsin**inhibitor* PY 1998

L19 ANSWER 23 OF 53 CA COPYRIGHT 2001 ACS
TI Production of a hybrid protein consisting of the N-terminal fragment of urokinase and the C-terminal *domain* of *urinary**trypsin**inhibitor* in Escherichia coli PY 1998

L19 ANSWER 24 OF 53 CA COPYRIGHT 2001 ACS
TI The crystal structure of *Bikunin* from the inter-α- inhibitor complex: a serine protease inhibitor with two Kunitz domains PY 1998

L19 ANSWER 25 OF 53 CA COPYRIGHT 2001 ACS
TI Expression and localization of *urinary**trypsin**inhibitor* in the rat embryo PY 1997

L19 ANSWER 26 OF 53 CA COPYRIGHT 2001 ACS
TI Role of O-linked carbohydrate of human *urinary**trypsin**inhibitor* on its lysosomal membrane-stabilizing property PY 1998

L19 ANSWER 27 OF 53 CA COPYRIGHT 2001 ACS
TI Cloning of a new Kunitz-type protease inhibitor with a putative transmembrane *domain* overexpressed in pancreatic cancer PY 1998

L19 ANSWER 28 OF 53 CA COPYRIGHT 2001 ACS AN 127:246958 CA
TI Inhibition of tryptase TL2 from human T4+ lymphocytes and inhibition of HIV-1 replication in H9 cells by recombinant aprotinin and *bikunin* homologs
AU Brinkmann, Thomas; Schaefers, Jochen; Guertler, Lutz; Kido, Hiroshi; Niwa, Yasuharu; Katunuma, Nobuhiko; Tschesche, Harald
CS Institut fur Laboratoriums- und Transfusionsmedizin, Herzund Diabeteszentrum Nordrhein-Westfalen, Universitatsklinik der Ruhr-Universitat Bochum, Bad Oeynhausen, Germany
SO J. Protein Chem. (1997), 16(6), 651-660 CODEN: JPCHD2; ISSN: 0277-8033 PB Plenum DT Journal LA English
AB The serine esterase TL2 from human T4+ lymphocytes is a binding component to HIV-1 glycoprotein gp120 and seems to play a role in the HIV-1 infection mechanism. Recombinant variants of the Kunitz-type serine proteinase inhibitor aprotinin were investigated for their ability to inhibit tryptase TL2 and the binding of gp120 to this enzyme. Furthermore, the viral replication of HIV-1 was investigated in H9 cell cultures under the influence of recombinant aprotinin and *bikunin* variants. In contrast to native aprotinin, the recombinant variant [Arg15, Phe17, Glu52]aprotinin with a reactive-site sequence homologous to the V3 loop of HIV-1 gp120 showed a specific inhibition of tryptase TL2 (>80%). However, the [Leu15, Phe17, Glu52]aprotinin variant with hydrophobic subsites was the most potent inhibitor of the binding of gp120 to tryptase TL2 (68%). The authors' results show that the enzyme activity of purified tryptase TL2 is inhibited not only by variants with basic amino acids, but also those with hydrophobic residues in the reactive-site region. Therefore, tryptase TL2 is not a typical trypsin-like or chymotrypsin-like protease. Investigations on inhibition of HIV-1 replication in H9 cell cultures showed that tryptase TL2 is involved in the mechanism of virus internalization into human lymphocytes. The [Leu15, Phe17, Glu52]aprotinin showed a retardation of syncytium formation over a period of 5 days in a 1 μM concn. Similar investigations were performed with recombinant variants of *bikunin*, the light chain of human inter-α-trypsin inhibitor. Only the single-headed variant [Arg94].delta.2bikunin inhibited slightly the syncytium formation over a period of 2 days in a 2.2 μM concn. Wild-type *bikunin* and all full-length variants showed no effect, possibly due to steric hindrance by the second *domain* of the double-headed inhibitor.

L19 ANSWER 29 OF 53 CA COPYRIGHT 2001 ACS AN 127:216908 CA
TI Purification and characterization of a novel protease inhibitor specific to hepatocyte growth factor activator
AU Kawaguchi, Toshiya; Shimomura, Takeshi; Denda, Kimitoshi; Kitamura, Akiko; Kondo, Jun; Kito, Masahiro; Kagaya, Shinji; Qin, Li; Takata, Hiroyuki; Miyazawa, Keiji; Kitamura, Naomi
CS Yokohama Research Center, Mitsubishi Chemical Corporation, Yokohama, 227, Japan
SO Anim. Cell Technol.: Basic Appl. Aspects, Proc. Annu. Meet. Jpn. Assoc. Anim. Cell Technol., 8th (1997), Meeting Date 1995, 403-407. Editor(s): Funatsu, Kazumori; Shirai, Yoshihito; Matsushita, Taku. Publisher: Kluwer, Dordrecht, Neth. CODEN: 64WUA2 DT Conference LA English
AB *Hepatocyte**growth**factor**activator**inhibitor* (HAI) was purified from serum-free conditioned medium of a human stomach carcinoma cell line, and a partial amino acid sequence was detd. The sequence data revealed that HAI is a novel proteinase inhibitor which contains a Kunitz-type serine proteinase inhibitory *domain*. Purified HAI inhibited hepatocyte growth factor activator in a concn.-dependent manner, but had no significant effect on factor XIIa.

L19 ANSWER 30 OF 53 CA COPYRIGHT 2001 ACS
TI Metastasis inhibitor proteins consisting of *urinary**trypsin**inhibitor* and urokinase PY 1997 1997 1999

L19 ANSWER 31 OF 53 CA COPYRIGHT 2001 ACS AN 127:104313 CA
TI Novel protease inhibitory activities of the second *domain* of urinary trypsin inhibitory (R-020) and its effect on sepsis-induced organ injury in rat
AU Murata, A.; Toda, H.; Uda, K.-I.; Nakagawa, H.
CS Department of Surgery II, Osaka University Medical School, Suita City, 565, Japan
SO Immune Consequences Trauma, Shock Sepsis: Mech. Ther. Approaches, [Int. Congr.], 3rd (1996), Meeting Date 1994, Volume 1, 78-81. Editor(s): Faist, Eugen; Baue, Arthur E.; Schildberg, F. W. Publisher: Pabst Science Publishers, Lengerich, Germany. CODEN: 64SOAW DT Conference LA English
AB The authors used the recombinant protein R-020 coding the second *domain* of the Kunitz-type proteinase inhibitor in human *urinary**trypsin**inhibitor* to examn. its therapeutic efficacy in a rat in vivo sepsis model. R-020 could protect the host from organ injuries occurring in septic reactions, as shown by the overall improved survival rate of the rats and the strongly attenuated pathol. changes in the lungs. Thus, R-020 appears to be effective in treating sepsis-related organ dysfunction.

L19 ANSWER 32 OF 53 CA COPYRIGHT 2001 ACS
TI Recombinant preparation in Pichia of human protease inhibitor mutants with improved activity on inhibiting neutrophil elastase PY 1997

L19 ANSWER 33 OF 53 CA COPYRIGHT 2001 ACS
TI Identification and cloning of human placental *bikunin*, a novel serine protease inhibitor containing two Kunitz domains PY 1997

L19 ANSWER 34 OF 53 CA COPYRIGHT 2001 ACS
TI Characterization of placental *bikunin*, a novel human serine protease inhibitor PY 1997

L19 ANSWER 35 OF 53 CA COPYRIGHT 2001 ACS
TI *Urinary**trypsin**inhibitor*: production in the liver and reabsorption in the kidney of the rat PY 1996

L19 ANSWER 36 OF 53 CA COPYRIGHT 2001 ACS
TI Mechanism of tumor cell-induced extracellular matrix degradation. Inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis PY 1996

L19 ANSWER 37 OF 53 CA COPYRIGHT 2001 ACS
TI Human *urinary**trypsin**inhibitor* and fragments and their recombinant preparation with Pichia PY 1996

L19 ANSWER 38 OF 53 CA COPYRIGHT 2001 ACS
TI Sequence analysis and evolutionary aspects of piscine α-1- microglobulin/ *bikunin* mRNA transcripts PY 1995

L19 ANSWER 39 OF 53 CA COPYRIGHT 2001 ACS AN 123:221366 CA
TI Novel blood coagulation factor inhibitory activities of the second *domain* of urinary**trypsin**inhibitor* and its variants
AU Nii, Atsushi; Morishita, Hideaki; Hirose, Jiro; Yamakawa, Toru; Kanamori, Toshinori
CS Biosciences Research Laboratory, Mochida Pharmaceutical Co., Ltd., Japan
SO Nippon Kessen Shiketsu Gakkaishi (1995), 6(3), 203-7 CODEN: NKSGEL; ISSN: 0915-7441 DT Journal; General Review LA Japanese

AB A review, with 15 refs., on the title topic, discussing mol. cloning, expression, and purifn. of the second *domain* (R-020) of *urinary**trypsin**inhibitor*; inhibitory activities of R-020; and prepn. of R-020 variants.

L19 ANSWER 40 OF 53 CA COPYRIGHT 2001 ACS
TI The three heavy-chain precursors for the inter-α-inhibitor family in mouse: new members of the multicopper oxidase protein group with differential transcription in liver and brain PY 1995

L19 ANSWER 41 OF 53 CA COPYRIGHT 2001 ACS
TI Inhibition of tumor cell invasion through matrigel by a peptide derived from the *domain* II region in urinary trypsin inhibition PY 1995

L19 ANSWER 42 OF 53 CA COPYRIGHT 2001 ACS
TI Kunitz-type trypsin inhibitor prevents LPS-induced increase of cytosolic free Ca2+ in human neutrophils and HUVEC cells PY 1995

L19 ANSWER 43 OF 53 CA COPYRIGHT 2001 ACS
TI Isolation and characterization of novel blood coagulation factor Xa (FXa) inhibitor (R-020) and its variants PY 1994

L19 ANSWER 44 OF 53 CA COPYRIGHT 2001 ACS
TI Inhibitory effect of a conjugate between human urokinase and *urinary**trypsin**inhibitor* on tumor cell invasion in vitro PY 1995

L19 ANSWER 45 OF 53 CA COPYRIGHT 2001 ACS AN 122:234086 CA
TI Activities of the second *domain* of human *urinary**trypsin**inhibitor* on various enzymes
AU Nagase, Yasukazu
CS Department of Microbiology, Kyoto Prefectural University of Medicine, Kyoto, Japan
SO Kyoto-furitsu Ika Daigaku Zasshi (1994), 103(5), 623-35 CODEN: KFIZAO; ISSN: 0023-6012 DT Journal LA Japanese
AB To investigate the inhibitory spectrum of human *urinary**trypsin**inhibitor* (UTI) in more detail, cDNA coding for its 2nd *domain* was obtained and an expression plasmid pM552 was constructed. The product secreted into the cultured supernatant of transformant Escherichia coli JE5505 contg. the plasmid was then isolated. The recombinant 2nd *domain* of UTI was purified by ammonium sulfate pptn., gel filtration chromatog., ion-exchange chromatog. and reverse phase chromatog. In addn. to its already known inhibitory activities, the 2nd *domain* mol. demonstrated a concn.-dependent inhibitory effect on human blood-coagulation factor Xa and human plasma kallikrein. Moreover, it prolonged the plasma-based activated partial thromboplastin time.

L19 ANSWER 46 OF 53 CA COPYRIGHT 2001 ACS
TI Protective effect of recombinant neutrophil elastase inhibitor (R-020) on sepsis-induced organ injury in rat PY 1994

L19 ANSWER 47 OF 53 CA COPYRIGHT 2001 ACS
TI Monoclonal antibodies against trypsin-binding *domain* of human *urinary**trypsin**inhibitor* PY 1994

L19 ANSWER 48 OF 53 CA COPYRIGHT 2001 ACS AN 121:197625 CA
TI Design of variants of the second *domain* of *urinary**trypsin**inhibitor* (R-020) with increased factor Xa inhibitory activity
AU Nii, Atsushi; Morishita, Hideaki; Yamakawa, Toru; Matsusue, Tomokazu; Hirose, Jiro; Miura, Toshihisa; Isaji, Mitsuko; Horisawa, Yoshifumi; Sugihara, Keisuke; et al.
CS Bioscience Research Laboratory, Mochida Pharmaceutical Co., Ltd., Tokyo, 115, Japan
SO J. Biochem. (Tokyo) (1994), 115(6), 1107-12 CODEN: JOBIAO; ISSN: 0021-924X DT Journal LA English
AB The second *domain* (R-020) of human *urinary**trypsin**inhibitor* (UTI) exerts similar inhibitory activities on trypsin, α-chymotrypsin, leukocyte elastase, and plasmin to those of UTI itself, and addnl. inhibits coagulation factor Xa(FXa) and plasma kallikrein, on both of which UTI has no inhibitory effect. In the present study, the authors attempted to increase this FXa-inhibitory activity by modeling the structure of R-020-FXa complex and substituting one or two amino acids in R-020 using recombinant DNA technol. Mol. modeling of R-020 and FXa was performed with ref. to x-ray anal. of the complex of bovine pancreatic trypsin inhibitor (BPTI) and bovine trypsin to det. the site of amino acid modification. The expression plasmids into which R-020 genes with base substitution were inserted were prepd. and introduced into Escherichia coli to express R-020 variants. The resulting variants were purified and their enzyme inhibitory activities were measured. The FXa-inhibitory activity was increased in four variants with single amino acid substitution. With another four variants having two amino acid substitutions involving combinations of the above single amino acid substitutions, the FXa-inhibitory activity was further increased. Because the electrostatic interaction within R-020-FXa complex seemed stronger in these R-020 variants, this increase in FXa-inhibitory effect was speculated to be a consequence of more potent binding between the enzyme and the inhibitor.

L19 ANSWER 49 OF 53 CA COPYRIGHT 2001 ACS
TI TSG-6, an Arthritis-Associated Hyaluronan Binding Protein, Forms a Stable Complex with the Serum Protein Inter-α-inhibitor PY 1994

L19 ANSWER 50 OF 53 CA COPYRIGHT 2001 ACS
TI Monoclonal antibodies that recognize trypsin binding *domain* of human *urinary**trypsin**inhibitor* PY 1993

L19 ANSWER 51 OF 53 CA COPYRIGHT 2001 ACS AN 120:211333 CA
TI Novel factor Xa and plasma kallikrein inhibitory activities of the second Kunitz-type inhibitory *domain* of *urinary**trypsin**inhibitor*
AU Morishita, Hideaki; Yamakawa, Toru; Matsusue, Tomokazu; Kusuyama, Takeshi; Sameshima-Aruga, Rie; Hirose, Jiro; Nii, Atsushi; Miura, Toshihisa; Isaji, Mitsuko; et al.
CS Biosci. Res. Lab., Mochida Pharm. Co. Ltd., Tokyo, 115, Japan
SO Thromb. Res. (1994), 73(3-4), 193-204 CODEN: THBRAA; ISSN: 0049-3848 DT Journal LA English
AB *Urinary**trypsin**inhibitor* is a glycoprotein with a structure in which 2 Kunitz-type inhibitory domains are linked in a row. Two genes were isolated encoding the 70-amino-acid sequence from the 78th amino acid (Thr) to the C-terminal and the 68-amino-acid sequence from the 80th (Ala) to C-terminal of human *urinary**trypsin**inhibitor*, both which correspond to the 2nd Kunitz-type inhibitory *domain*, and then expression plasmids were constructed by ligating it to the Escherichia coli alk. phosphatase signal peptide gene. These plasmids under the control of the tryptophan promoter expressed the 2nd *domain* in E. coli strain JE5505 which lacks the membrane lipoprotein. The recombinant 2nd *domain* purified from the culture supernatant of the transformant inhibited trypsin, plasmin, leukocyte elastase, and chymotrypsin which are known to be inhibited by *urinary**trypsin**inhibitor*.In addn. it inhibited blood coagulation factor Xa and plasma kallikrein in a concn.-dependent and competitive manner, and significantly prolonged the plasma-based activated partial thromboplastin time (APTT). The truncated natural counterpart obtained by a limited degrdn. of human *urinary**trypsin**inhibitor* revealed identical inhibitory activities.

L19 ANSWER 52 OF 53 CA COPYRIGHT 2001 ACS
TI Kunitz-type proteinase inhibitors derived by limited proteolysis of the inter-α-trypsin inhibitor. V. Attachments of carbohydrates in the human *urinary**trypsin**inhibitor* isolated by affinity chromatography Y 1981

L19 ANSWER 53 OF 53 CA COPYRIGHT 2001 ACS
TI Kunitz-type proteinase inhibitors derived by limited proteolysis of the inter-α-trypsin inhibitor. IV. The amino acid sequence of the human *urinary**trypsin**inhibitor* isolated by affinity chromatography PY 1981

02apr01 08:53:28 User208600 Session D1382.1
File 155:MEDLINE(R) 1966-2000/Dec W4)format only 2000
Dialog Corporation

Set	Items	Description
S1	23	"APROTININ --ANALOGS AND DERIVATIVES --AA"
S2	5638	"APROTININ"
S3	1029	KUNITZ
S4	156	S2 AND S3
S5	38460	GLYCOSYL?
S6	1	S4 AND S5
S7	2581	"SERINE PROTEINASE INHIBITORS"
S8	2535	DC="D27.505.373.745.800."
S9	0	S8 AND S3 AND S5
S10	94	S8 AND S3
S11	806	"RECOMBINANT PROTEINS -- PHARMACOKINETICS --PK"
[redacted]	14356	"RECOMBINANT PROTEINS -- [redacted]RMACOLOGY --PD"
S13	25964	"RECOMBINANT PROTEINS -- METABOLISM --ME"
S14	3394	"RECOMBINANT PROTEINS -- ADMINISTRATION AND DOSA"
S15	40	S8 AND S5
S16	76599	"RECOMBINANT PROTEINS"
S17	10	S15 AND S16
S18	1224	S13 AND S5
S19	1	S18 AND S3
S20	58	S11 AND S5
S21	0	S20 AND S3
S22	207	S12 AND S5 NOT (S17 OR S20)
S23	2	S3 AND S22
S24	66	S14 AND S5

1/6/1 10463203 99447443
NMR characterization of partially folded and unfolded conformational ensembles of proteins. 1999

[redacted]:0195744 20035840
[redacted]eering an unnatural Nalpha-anchored disulfide into BPTI by total chemical synthesis: structural and functional consequences. Oct 22 1999

1/6/3 10166705 99425321
Miniaturized proteins: the backbone cyclic proteinomimetic approach. Sep 17 1999

1/6/4 10120457 99083921
Selective bridging of bis-cysteinyl residues by arsonous acid derivatives as an approach to the characterization of protein tertiary structures and folding pathways by mass spectrometry.Nov 15 1998

1/6/5 10085470 97408608
Inhibition of tryptase TL2 from human T4+ lymphocytes and inhibition of HIV-1 replication in H9 cells by recombinant aprotinin and bikunin homologues. Aug 1997

1/6/6 10044492 99376590
Design of synthetic bactericidal peptides derived from the bactericidal domain P(18-39) of aprotinin. Aug 17 1999

1/6/7 09445582 98191324
13C NMR, X-ray, and differential scanning calorimetry investigations of truncated BPTI (aprotinin) analogues. Mar 17 1998

1/6/8 09186031 97311760
A folded protein can be transported across the chloroplast envelope and thylakoid membranes. May 1997

1/6/9 08978653 97063015
Internal packing conditions and fluctuations of amino acid residues in globular proteins. Feb 1996

1/6/10 08700411 96041291
Characterisation of a novel series of aprotinin-derived anticoagulants. II. Comparative antithrombotic effects on primary thrombus formation in vivo. Aug 1995

1/6/11 08700410 96041290
Characterisation of a novel series of aprotinin-derived anticoagulants. I. In vitro and pharmacological properties. Aug 1995

1/6/12 08681516 95077978
Binding of native and [homoserine lactone-52]-52,53-seco-bovine basic pancreatic trypsin inhibitor (Kunitz inhibitor) to porcine pancreatic beta-kallikrein-B and bovine alpha-chymotrypsin: thermodynamic study. Mar 1994

1/6/13 08392466 95292106
Partially folded, molten globule and molten coil states of bovine pancreatic trypsin inhibitor. Mar 1995

1/6/14 08170162 95073829
BPTI backbone variants and implications for inhibitory activity. Aug 1994

1/6/15 07790787 94083409
Amino acid replacement that eliminates kinetic traps in the folding pathway of pancreatic trypsin inhibitor. Dec 28 1993

1/6/16 07786619 93385153
Differential in vitro translation of the precursors of bovine pancreatic trypsin inhibitor and its isoinhibitor II is controlled by the 5'-end region of their mRNAs. Sep 23 1993

1/6/17 07786478 93381696
On the biosynthesis of bovine pancreatic trypsin inhibitor (BPTI). Structure, processing, folding and disulphide bond formation of the precursor in vitro and in microsomes. Aug 20 1993

1/6/18 07297470 94122491
Studies on the extraction of DesPro(2)-Val15-Leu17-aprotinin from the culture broth of a recombinant Saccharomyces cerevisiae. 93 1992

1/6/19 07295260 93122967
Solid-phase synthesis of bovine pancreatic trypsin inhibitor (BPTI) and two analogues. A chemical approach for evaluating the role of disulfide bridges in protein folding and stability. Sep-Oct 1992

1/6/20 05842139 89093102
Circular pancreatic trypsin inhibitor. A novel substrate for studies on intracellular proteolysis. Jan 15 1989

1/6/21 05826048 88025064
Solvent exchange of buried water and hydrogen exchange of peptide NH groups hydrogen bonded to buried waters in bovine pancreatic trypsin inhibitor. Aug 11 1987

1/6/22 05825111 88000558
Stability studies on derivatives of the bovine pancreatic trypsin inhibitor. Jun 16 1987

1/6/23 05800165 86030285
Comparative studies of conformation and internal mobility in native and circular basic pancreatic trypsin inhibitor by 1H nuclear magnetic resonance in solution. Oct 15 1985

4/6/1 10400295 20233720
Protease nexin II interactions with coagulation factor XIa are contained within the Kunitz protease inhibitor domain of protease nexin II and the factor XIa catalytic domain. Apr 25 2000

4/6/2 10316570 20149822
Structure-activity relationships for the interaction of bovine pancreatic trypsin inhibitor with an intracellular site on a large conductance Ca(2+)-activated K(+) channel. Feb 29 2000

4/6/3 10139626 99410480
Generation of catalytically active granzyme K from Escherichia coli inclusion bodies and identification of efficient granzyme K inhibitors in human plasma. Sep 17 1999

4/6/4 10132470 99282177
Thermodynamic criterion for the conformation of P1 residues of substrates and of inhibitors in complexes with serine proteinases. Jun 1 1999

4/6/5 10125084 99158445
Reduction of sodium deoxycholic acid-induced scratching behaviour by bradykinin B2 receptor antagonists. Jan 1999

4/6/6 10123112 99126538
Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant. Feb 5 1999

4/6/7 10122542 99115665
The kunitz protease inhibitor form of the amyloid precursor protein (KPI/APP) inhibits the proneuropeptide processing enzyme prohormone thiol protease (PTP). Colocalization of KPI/APP and PTP in secretory vesicles. Jan 29 1999

4/6/8 10098106 98153773
Role of O-linked carbohydrate of human urinary trypsin inhibitor on its lysosomal membrane-stabilizing property. Feb 13 1998

4/6/9 10085470 97408608
Inhibition of tryptase TL2 from human T4+ lymphocytes and inhibition of HIV-1 replication in H9 cells by recombinant aprotinin and bikunin homologues. Aug 1997

4/6/10 10076504 97234622
The rkpGHI and -J genes are involved in capsular polysaccharide production by Rhizobium meliloti. Apr 1997

4/6/11 09975658 99281764
Secretion of protease nexin-II/amyloid beta protein precursor by human colorectal carcinoma cells and its modulation by cytokines/growth factors and proteinase inhibitors. Apr 1999

4/6/12 09913186 99126501
Simultaneous binding of basic peptides at intracellular sites on a large conductance Ca2+-activated K+ channel. Equilibrium and kinetic basis of negatively coupled ligand interactions. Feb 1999

4/6/13 09899445 99180001
Conformational and functional variability supported by the BPTI fold: solution structure of the Ca2+ channel blocker calcicludine. Mar 1 1999

4/6/14 09802528 99141404
Evolutionary trace analysis of the Kunitz/BPTI family of proteins: functional divergence may have been based on conformational adjustment. Jan 29 1999

4/6/15 09741160 99013318
Activity of secreted Kunitz domain 1 variants of tissue factor pathway inhibitor. Oct 1998

4/6/16 09716676 98422077

Use of protease inhibitors to improve calcitonin absorption from the small and large intestine in rats. Aug 1998

4/6/17 09608502 98381064
Aprotinin, the first competitive protein inhibitor of NOS activity. Aug 10 1998

4/6/18 09608287 98391184
Recombinant Kunitz protease inhibitor ameliorates reperfusion injury in rat lung transplantation. Aug 1998

4/6/19 09427674 98148043
Relative increase in Alzheimer's disease of soluble forms of cerebral Abeta amyloid protein precursor containing the Kunitz protease inhibitory domain. Feb 27 1998

4/6/20 09406452 98138472
A role for amyloid precursor-like protein 2 in corneal epithelial wound healing. Feb 1998

4/6/21 09366665 97445596
Crystal structures of bovine chymotrypsin and trypsin complexed to the inhibitor domain of Alzheimer's amyloid beta-protein precursor (APPI) and [redacted] pancreatic trypsin inhibitor (BPTI): engineering of inhibitors with altered [redacted]ficities. Sep 1997

4/6/22 09280468 97357443
Cloning, expression, and mutagenesis of trypsin inhibitor ETIb from Erythrina variegata seeds. Jun 1997

4/6/23 09232202 97410331
Solution structure and backbone dynamics of the human alpha3-chain type VI collagen C-terminal Kunitz domain,. Aug 26 1997

4/6/24 09205032 97323288
Crystal structure of the bovine alpha-chymotrypsin: Kunitz inhibitor complex. An example of multiple protein:protein recognition sites. Jan-Feb 1997

4/6/25 09181637 97357286
The thrombin E192Q-BPTI complex reveals gross structural rearrangements: implications for the interaction with antithrombin and thrombomodulin. Jun 2 1997

4/6/26 09146538 97266276
Recent studies on dendrotoxins and potassium ion channels. Jan 1997

4/6/27 09130341 97245053
[redacted] of amino acid residue conservation in the 3D structures of the Kunitz [redacted]proteinase inhibitors: how do variants from snake venom differ? Feb [redacted]

4/6/28 09100907 97196846
Strong crossreaction of human anti- aprotinin antibodies from heart transplant patient with [Arg15] aprotinin. Jan 1997

4/6/29 09048106 96388868
Plant serine proteinase inhibitors. Structure and biochemical applications on plasma kallikrein and related enzymes. May 1996

4/6/30 09043442 96283825
Conversion of the Kunitz -type module of collagen VI into a highly active trypsin inhibitor by site-directed mutagenesis. Jun 1 1996

4/6/31 09042465 96264920
Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin. Jun 18 1996

4/6/32 09035858 97080517
Inducible expression of a heterologous protein in Hansenula polymorpha using the alcohol oxidase 1 promoter of Pichia pastoris. Oct 24 1996

4/6/33 09020251 97161089
Elucidation of the origin of multiple conformations of the human alpha 3-chain type VI collagen C-terminal Kunitz domain: the reorientation of the Trp21 ring. Dec 1996

4/6/34 09007168 96387211
The disulfide folding pathway of tick anticoagulant peptide (TAP), a Kunitz-type inhibitor structurally homologous to BPTI. Sep 10 1996

4/6/35 08895430 97128614
An evolutionarily conserved binding site for serine proteinase inhibitors in large conductance calcium-activated potassium channels. Dec 17 1996

4/6/36 08879565 97094845
The alternatively spliced Kunitz protease inhibitor domain alters amyloid beta protein precursor processing and amyloid beta protein production in cultured cells. Nov 29 1996

4/6/37 08878580 97064258
An investigation of the binding of protein proteinase inhibitors to trypsin by electrospray ionization mass spectrometry. Oct 28 1996

4/6/38 08878328 97102783
The ornithodorin-thrombin crystal structure, a key to the TAP enigma? Nov 15 1996

4/6/39 08800468 96369822
Sprouting and abnormal contacts of nonmedullated axons, and deposition of extracellular material induced by the amyloid precursor protein (APP) and other protease inhibitors. Apr 29 1996

4/6/40 08780445 96351888
Primary structure of a Kunitz-type trypsin inhibitor from Enterolobium contortisiliquum seeds. Mar 1996

4/6/41 08722679 96264919
Iterative optimization of high-affinity proteases inhibitors using phage display. 1. Plasmin. Jun 18 1996

4/6/42 08705338 96132624
Characterization of a membrane protease from rat submaxillary-gland mitochondria that possess thrombin-like activity. Jan 1 1996

4/6/43 08699724 96029621
Potent and selective Kunitz domain inhibitors of plasma kallikrein designed by phage display. Oct 27 1995

4/6/44 08681516 95077978
Binding of native and [homoserine lactone-52]-52,53-seco-bovine basic pancreatic trypsin inhibitor (Kunitz inhibitor) to porcine pancreatic beta-kallikrein-B and bovine alpha-chymotrypsin: thermodynamic study. Mar 1994

4/6/45 08657095 96230240
A novel marsupial protein expressed by the mammary gland only during the early lactation and related to the Kunitz proteinase inhibitors. Jun 1 1996

4/6/46 08651181 96217894
Thermodynamic stability effects of single peptide bond hydrolysis in protein inhibitors of serine proteinases. Mar 8 1996

4/6/47 08642145 96206691
Studies on dressings for mucosa of the oral cavity. Part 3: Effect of preparation technology on the physical and chemical properties of stomatological xerogel dressings. Apr 1996

4/6/48 08629283 96182215
Genetically engineered serine protease inhibitor for hemostasis after cardiac operations. Apr 1996

4/6/49 08537879 96360459
Characterisation of a novel Kunitz-type molecule from the trematode Fasciola hepatica. Oct 1995

4/6/50 08447334 96028018
Expression, purification and functional characterisation of a Kunitz -type module from chicken type VI collagen. Oct 24 1995

4/6/51 08407478 96027617
Kalicludines and kaliseptine. Two different classes of sea anemone toxins for voltage sensitive K+ channels. Oct 20 1995

4/6/52 08407341 96032709
Enhanced plasmin inhibition by a reactive center lysine mutant of the Kunitz -type protease inhibitor domain of the amyloid beta-protein precursor. Sep 29 1995

4/6/53 08394827 95354214
LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Jul 28 1995

4/6/54 08391875 95276660
NMR structure determination of tick anticoagulant peptide (TAP). Feb 1995

4/6/55 08390179 95227392
Mitosis of Schwann cells and demyelination are induced by the amyloid precursor protein and other protease inhibitors in the rat sciatic nerve. Jan 1 1995

4/6/56 08389092 95182468
The 1.6 A structure of Kunitz-type domain from the alpha 3 chain of human type VI collagen. Mar 10 1995

4/6/57 08364622 95375151
Functional and immunologic methods for the measurement of human tissue factor pathway inhibitor. Jun 1995

4/6/58 08208607 94333399
Denaturation of free and complexed bovine trypsinogen with the calcium ion, dipeptide Ile-Val and basic pancreatic trypsin inhibitor (Kunitz). Aug 1 1994

4/6/59 08206949 94308069
Glu192-->Gln substitution in thrombin yields an enzyme that is effectively inhibited by bovine pancreatic trypsin inhibitor and tissue factor pathway inhibitor. Jul 15 1994

4/6/60 08171848 95121217
Aprotinin , a Kunitz -type protease inhibitor, stimulates skeletal muscle differentiation. Dec 1994

4/6/61 08170159 95073791
Protective effect of recombinant neutrophil elastase inhibitor (R-020) on sepsis-induced organ injury in rat. Aug 1994

4/6/62 08168943 95045506
Recombinant expression and properties of the Kunitz -type protease-inhibitor module from human type VI collagen alpha 3(VI) chain. Oct 15 1994

4/6/63 08167408 95010138
Heterotropic modulation of the protease-inhibitor-recognition process. Cations effect the binding properties of alpha-chymotrypsin. Oct 1 1994

4/6/64 08166354 94360540
[Natural proteinase inhibitors as a basis for creating new drugs] Prirodnye ingibitory proteinaz kaka osnova dlia sozdaniia novykh lekarstvennykh sredstv. May-Jun 1994

4/6/65 08162246 94264986
Proteinase inhibitors of the Kunitz family in fallow deer organs: a comparative study. Apr 1994

4/6/66 07853053 93285153
Binding of bovine pancreatic trypsin inhibitor to heparin binding

protein/CAP37/azurocidin. Interaction between a Kunitz-type inhibitor and a proteolytically inactive serine proteinase homologue. May 15 1993

4/6/67 07850312 93220080
The role of bradykinin in mediating ischemic brain edema in rats. Apr 1993

4/6/68 07793397 94180158
Binding of bovine basic pancreatic trypsin inhibitor (Kunitz) as well as bovine and porcine pancreatic secretory trypsin inhibitor (Kazal) to human cathepsin G: a kinetic and thermodynamic study. 1993

4/6/69 07787585 94013211
High-performance liquid chromatographic separation of aprotinin-like inhibitors and their determination in very small amounts. Aug 11 1993

4/6/70 07786604 93384789
Colloidal carbon particles as a new label for rapid immunochemical test methods: quantitative computer image analysis of results. Aug 1993

4/6/71 07785055 93348617
Does noggin head a new class of Kunitz domain? [see comments] Jun 1993

4/6/[redacted]2 07778393 93170317
Sequence-specific 1H-NMR assignment and secondary structure of black mamba dendrotoxin I, a highly selective blocker of voltage-gated potassium channels. Feb 1 1993

4/6/73 07481409 93129295
Inhibition of mite protease (Df-protease) with protease inhibitors. Dec 1992

4/6/74 07478038 93051367
Protease inhibitor display M13 phage: selection of high-affinity neutrophil elastase inhibitors. Nov 2 1992

4/6/75 07471824 92318008
Raw soybeans stimulate human pancreatic proteinase secretion. Jul 1992

4/6/76 07471770 92317085
Isolation and characterization of a novel trypsin-like protease found in rat bronchiolar epithelial Clara cells. A possible activator of the viral fusion glycoprotein. Jul 5 1992

4/6/77 07461926 92087518
[Activity of tissue and plasma kallikrein and level of their precursors in eye tissue structures and media of healthy rabbits] Aktivnost' tkanevogo i plazmennogo kallikreinov i uroven' ikh predshestvennikov v tkanevykh [redacted]turakh i sredakh glaza zdorovogo krolika. Jul-Aug 1991

4/6/78 07445952 91072409
A novel membrane-bound serine esterase in human T4+ lymphocytes immunologically reactive with antibody inhibiting syncytia induced by HIV-1. Purification and characterization. Dec 15 1990

4/6/79 07442756 90372214
Studies on relation of bradykinin to ischemic brain edema in stroke-resistant spontaneously hypertensive rat. 1990

4/6/80 07441397 90336775
Does the Kunitz domain from the Alzheimer's amyloid beta protein precursor inhibit a kallikrein responsible for post-translational processing of nerve growth factor precursor? Jul 16 1990

4/6/81 07426775 92260111
Inhibition of the activation of Hageman factor (factor XII) by aprotinin (Trasylol) [see comments] May 1992

4/6/82 07390552 92320894
Amyloid beta protein precursors with kunitz-type inhibitor domains and acetylcholinesterase in cerebrospinal fluid from patients with dementia of the Alzheimer type. May 1992

4/6/83 07367782 91341461
On the interaction of bovine pancreatic trypsin inhibitor with maxi Ca(2+)-activated K+ channels. A model system for analysis of peptide-induced subconductance states Jun 1991

4/6/84 07358918 91200669
Synthesis and characterization of the Kunitz protease-inhibitor domain of the beta-amyloid precursor protein. Feb 15 1991

4/6/85 07286593 92322878
Studies on the mechanism of binding of serpins and serine proteases. Feb 1992

4/6/86 07284051 92260531
Binding of hirudin to human alpha, beta and gamma-thrombin. A comparative kinetic and thermodynamic study. May 5 1992

4/6/87 07240684 92297189
Acetaldehyde decreases the antitryptic activity of alpha 1-proteinase inhibitor. May-Jun 1992

4/6/88 06981195 92198388
K15R M52E) aprotinin is a weak Kunitz -type inhibitor of HIV-1 replication in H9 cells. 1991

4/6/89 06980530 92158860
Effects of proteolytic enzyme inhibitors on the nasal absorption of vasopressin and an analogue. Sep 1991

4/6/90 06976113 92035606
Quantitative analysis of human erythrocyte spectrin by sodium dodecyl sulfate-polyacrylamide gel electrophoresis using pancreatic trypsin inhibitor (Kunitz) as an internal standard. May 31 1991

4/6/91 06975949 92031488
Sequential NMR resonance assignment and structure determination of the Kunitz -type inhibitor domain of the Alzheimer's beta-amyloid precursor protein. Oct 29 1991

4/6/92 06963186 91099304
Primary structure and functional properties of cobra (Naja naja naja) venom Kunitz-type trypsin inhibitor. Dec 12 1990

4/6/93 06958672 90360602
Kunitz-type proteinase inhibitors in sheep and ox. 1990

4/6/94 06953511 90211628
A new inhibitor of plasmin and trypsin from porcine leukocytes. Jan 1990

4/6/95 06952023 90151612
Mosaic structure of globular domains in the human type VI collagen alpha 3 chain: similarity to von Willebrand factor, fibronectin, actin, salivary proteins and aprotinin type protease inhibitors. Feb 1990

4/6/96 06950358 92198402
A novel membrane-bound serine esterase in human T4(+)-lymphocytes is a binding protein of envelope glycoprotein gp120 of HIV-1. 1991

4/6/97 06751690 91340766
Role of the NADP/thioredoxin system in the reduction of alpha-amylase and trypsin inhibitor proteins. Aug 25 1991

4/6/98 06344864 89374818
Selective oxidation of methionine residues in Kunitz-type protease inhibitors. Jul 1989

4/6/99 06344054 89351611
Interaction between leukocytic elastase and Kunitz-type inhibitors from bovine spleen. Feb 1989

4/6/100 06332504 89076532
An acrosin inhibitor from boar seminal vesicle fluid immunologically related to the trypsin-kallikrein inhibitor (Kunitz). May 1988

4/6/101 06331875 89061635
Reaction of a tumour-associated trypsin inhibitor with serine proteinases associated with coagulation and tumour invasion. Sep 15 1988

4/6/102 06327155 88285356
Enhancement of transformed cell growth in agar by serine protease inhibitors. Jul 1988

4/6/103 06305797 87059638
Helodermatine, a kallikrein-like, hypotensive enzyme from the venom of Heloderma horridum horridum (Mexican beaded lizard). Dec 1 1986

4/6/104 06291561 86008178
Primary structure and antiproteolytic activity of a Kunitz-type inhibitor from bovine spleen. Sep 25 1985

4/6/105 05860279 91104622
Structure prediction of protease inhibitor region in amyloid precursor protein of Alzheimer's disease. Dec 1989

4/6/106 05855625 90054321
Direct amino acid analysis of proteins electroblotted onto polyvinylidene difluoride membrane from sodium dodecyl sulfate-polyacrylamide gel. Aug 15 1989

4/6/107 05845048 89171290
The domain structure of the inhibitor subunit of human inter-alpha-trypsin inhibitor reflects the exon structure of its gene. Mar 13 1989

4/6/108 05833651 88221840
Characterization and sequence determination of six aprotinin homologues from bovine lungs. Mar 1988

4/6/109 05831419 88163079
Pyroglutamyl- aprotinin , a new aprotinin homologue from bovine lungs--isolation, properties, sequence analysis and characterization using 1H nuclear magnetic resonance in solution. Dec 1987

4/6/110 05829130 88107008
Synthesis, cloning and expression of recombinant aprotinin. Oct 1987

4/6/111 05825579 88011216
Binding of the Ile-Val and Val-Val effector dipeptides to the binary adducts of bovine trypsinogen with Kunitz and Kazal inhibitors as well as the acylating agent p-nitrophenyl p-guanidinobenzoate. A thermodynamic and kinetic study. Apr 20 1987

4/6/112 05820633 87214230
Semisynthetic engineering of proteinase inhibitor homologues. May 27 1987

4/6/113 05816772 87112720
Binding of the bovine basic pancreatic trypsin inhibitor (Kunitz) to human Lys77-plasmin. Sep 20 1986

4/6/114 05806761 86188205
Proteolytic cleavage of human von Willebrand factor induced by enzyme(s) released from polymorphonuclear cells. May 1986

4/6/115 05791897 85110286
Various proteinase inhibitors decrease prolactin and growth hormone release by anterior pituitary cells. Feb 11 1985

4/6/116 04657527 84267851
Binding of the bovine basic pancreatic trypsin inhibitor (Kunitz) to human urinary kallikrein and to porcine pancreatic beta-kallikreins A and B. Jul 5 1984

4/6/117 04643492 83189165

Descriptors. *Blood Coagulation; *Factor VIIa--Antagonists and Inhibitors--AI; *Factor Xa--Antagonists and Inhibitors--AI; *Lipoproteins--Metabolism--ME; Aprotinin --Metabolism--ME; Lipoproteins--Pharmacology--PD; Recombinant Proteins--Metabolism--ME; Saccharomyces cerevisiae

CAS Registry No.: 0 (lipoprotein-associated coagulation inhibitor); 0 (recombinant Kunitz protease inhibitor); 0 (Lipoproteins); 0 (Recombinant Proteins); 9087-70-1 (Aprotinin) Enzyme No.: EC 3.4.21.21 (Factor VIIa); EC 3.4.21.6 (Factor Xa)

4/7/46 DIALOG(R)File 155:MEDLINE(R)(c) format only 2000 Dialog Corporation. All rts. reserv.

08651181 96217894

Thermodynamic stability effects of single peptide bond hydrolysis in protein inhibitors of serine proteinases.

Krokoszynska I; Otlewski J

Institute of Biochemistry, University of Wroclaw, Wroclaw, Poland.

Journal of molecular biology (ENGLAND) Mar 8 1996, 256 (4) p793-802, ISSN 0022-2836 Journal Code: J6V Languages: ENGLISH Document type: JOURNAL ARTICLE

Kunitz type soybean trypsin inhibitor (STI) and basic pancreatic trypsin inhibitor (BPTI) were used as model proteins to measure the thermodynamic consequences of single peptide bond hydrolysis. For each inhibitor the reactive site cleaved form was prepared and, additionally, each inhibitor was selectively cleaved at a Met residue. Selective cleavage generally led to reducing of the T(den) value from 7 K up to 75 K. For STI cleaved at Met84 a slight stabilization (increase of T(den) by 1.0 K) was observed. In terms of deltaG(den), the difference between the most extreme cleavage effect was 11.44 kcal/mole, much larger than resulting from the theoretical effects of crosslinks. It was found that hydrolysis of a single peptide bond affects not only entropy, but also enthalpy and heat capacity parameters. Moreover, the sign of change is opposite for two inhibitors: deltaH(den) and deltaS(den) increase for both cleaved forms of STI, while they decrease for two nicked forms of BPTI. To understand the stability effects, a thermodynamic cycle analysis was applied based on comparison of stabilities of intact and cleaved protein with peptide bond hydrolysis equilibria in native and denatured states. The cycle revealed a good agreement of the theoretical effect of crosslink elimination with a free energy difference for hydrolysis of a single peptide bond in a denatured protein. It appears that hydrolysis constants for single peptide bonds in a native protein span over at least 20 orders of magnitude. They are very low for peptide bonds placed in alpha-helices and very high if cleavage reaction leads to a formation of a new secondary structure element.

4/7/48 DIALOG(R)File 155:MEDLINE(R) (c) format only 2000 Dialog Corporation. All rts. reserv.

08629283 96182215

Genetically engineered serine protease inhibitor for hemostasis after cardiac operations.

Ohri SK; Paratt R; Becket JM; Brannan J; Hunt BJ; Taylor KM

Cardiothoracic Unit, Department of Surgery, Royal Postgraduate Medical School, Hammersmith Hospital, London, England.

Annals of thoracic surgery (UNITED STATES) Apr 1996, 61 (4) p1223-30, ISSN 0003-4975 Journal Code: 683 Languages: ENGLISH Document type: JOURNAL ARTICLE

BACKGROUND: The serine protease inhibitor aprotinin has been widely reported for its beneficial action in limiting blood loss after cardiopulmonary bypass (CPB). A potent human serine protease inhibitor known as protease nexin II or amyloid precursor protein has been recently isolated. A recombinant protein known as recombinant Kunitz protease inhibitor (rKPI; Scios Nova, Mountain View, CA) with sequence homology to the protease nexin II-amyloid precursor protein molecule has been manufactured. METHODS: Recombinant Kunitz protease inhibitor was assessed in an ovine model of CPB as a hemostatic agent after CPB. Sheep (n = 22) underwent CPB for 90 minutes. Two thoracic drains were sited and drain losses collected for a period of 3 hours after CPB. Wounds were subjectively assessed before closure for "dryness" using a visual analogue scale. Sheep were randomized to control (n = 8), aprotinin (n = 8), and rKPI (n = 6) groups. RESULTS: Control animals had a drain loss of 409.4 +/-39.4 mL/3 h, compared with 131.3 +/- 20.3 mL/3 h for the aprotinin group and 163.7 +/- 34.3 mL/3 h for the rKPI group (p = 0.16). Hemoglobin loss was 11.6 +/- 3.6, 6.02 +/- 2.1, and 4.6 +/- 1.2 g/3 h for the control, rKPI, and aprotinin groups respectively (p = 0.25). The subjective analysis of the wounds at the end of CPB found aprotinin (1.25 +/- 0.16; p < 0.05) and rKPI (1.17 +/- 0.17; p < 0.05) animals to score significantly lower than control animals (2.63 +/- 0.42). CONCLUSIONS: On the basis of these in vivo findings, genetic modification may yield a more efficacious serine protease inhibitor with the inherent advantages of using a human-based protein.

4/7/69 DIALOG(R)File 155:MEDLINE(R) (c) format only 2000 Dialog Corporation. All rts. reserv.

07787585 94013211

High-performance liquid chromatographic separation of aprotinin-like inhibitors and their determination in very small amounts.

Fioretti E; Eleuteri AM; Angeletti M; Ascoli F

Department of Molecular, Cellular and Animal Biology, University of Camerino, Italy.

Journal of chromatography (NETHERLANDS) Aug 11 1993, 617 (2) p308-12, ISSN 0021-9673 Journal Code: HQF Languages: ENGLISH Document type: JOURNAL ARTICLE

A reversed-phase high-performance liquid chromatographic method for the determination and quantitative recovery of fully active aprotinin (the basic pancreatic trypsin inhibitor or Kunitz inhibitor) and aprotinin -like inhibitors in amounts down to 0.5 micrograms is reported. The method, which allows separation of aprotinin isoinhibitors characterized by small differences in the primary structure with respect to aprotinin itself, appears to be suitable for the quantitation and identification of aprotinin -like inhibitors in human biological fluids, in which they appear to be present at very low levels.

6/6/1 08657095 96230240

A novel marsupial protein expressed by the mammary gland only during the early lactation and related to the Kunitz proteinase inhibitors. Jun 1 1996

10/6/1 10451514 20317343

[Proteins of the inter-alpha trypsin inhibitor (ITI) family. A major role in the biology of the extracellular matrix] Les proteines de la famille de l'ITI (inter-alpha trypsine inhibiteur). Un role majeur dans la biologie de la matrice extra-cellulaire. Apr 2000

10/6/2 10392094 20175262

Leucaena leucocephala serine proteinase inhibitor: primary structure and action on blood coagulation, kinin release and rat paw edema. Mar 7 2000

10/6/3 10295464 99359593

Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. Jun 1999

10/6/4 10294154 20080671

A double headed serine proteinase inhibitor--human plasma kallikrein and elastase inhibitor--from Boophilus microplus larvae. Dec 1999

10/6/5 10294150 20080667

Human plasma kallikrein and tissue kallikrein binding to a substrate based on the reactive site of a factor Xa inhibitor isolated from Bauhinia ungulata seeds. Dec 1999

10/6/6 10276602 20012988

Multiple sites of proteolytic cleavage to release soluble forms of hepatocyte growth factor activator inhibitor type 1 from a transmembrane form. Nov 1999

10/6/7 10275111 20058569

Predicted three-dimensional structural models of venom serine protease inhibitors and their interactions with trypsin and chymotrypsin. Oct 1999

10/6/8 10246545 20003131

Cryocrystallography of a Kunitz-type serine protease inhibitor: the 90 K structure of winged bean chymotrypsin inhibitor (WCI) at 2.13 A resolution. Nov 1999

10/6/9 10215519 99185302

Regulation of ProMMP-1 and ProMMP-3 activation by tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor. Feb 5 1999

10/6/10 10180419 99428273

Matrix localization of tissue factor pathway inhibitor-2/matrix-associate d serine protease inhibitor (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate: heparin accelerates the activity of TFPI-2/MSPI toward plasmin. Oct 1 1999

10/6/11 10171796 99395617

Protease activity in the larval stage of the parasitoid wasp, Eulophus pennicornis (Nees) (Hymenoptera: Eulophidae); effects of protease inhibitors. Aug 1999

10/6/12 10161681 99321854

Conformation of the primary binding loop folded through an intramolecular interaction contributes to the strong chymotrypsin inhibitory activity of the chymotrypsin inhibitor from Erythrina variegata seeds. Jul 1999

10/6/13 10139626 99410480

Generation of catalytically active granzyme K from Escherichia coli inclusion bodies and identification of efficient granzyme K inhibitors in human plasma. Sep 17 1999

10/6/14 10136719 99353466

Serine proteinase inhibitors in arthropod immunity. Jun-Jul 1999

10/6/15 10133727 99303582

Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. Jun 25 1999

10/6/16 10132470 99282177

Thermodynamic criterion for the conformation of P1 residues of substrates and of inhibitors in complexes with serine proteinases. Jun 1 1999

10/6/17 10123112 99126538

Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant. Feb 5 1999

10/6/18 10122542 99115665

The kunitz protease inhibitor form of the amyloid precursor protein (KPI/APP) inhibits the proneuropeptide processing enzyme prohormone thiol protease (PTP). Colocalization of KPI/APP and PTP in secretory vesicles. Jan 29 1999

10/6/19 10107938 98326432

[New studies on natural inhibitors of proteolytic ...

Interaction between serine (pro)enzymes, and Kazal and Kunitz inhibitors. Apr 15 1983

4/6/118 04474571 84179403

Multiple intermediates in the reaction of bovine beta-trypsin with bovine pancreatic trypsin inhibitor (Kunitz). Jan 1983

4/6/119 04462213 83144046

Isolation of pancreatic trypsin inhibitor from bovine pituitary glands. Mar 1983

4/6/120 04461763 83131627

Heterogeneity of the basic pancreatic inhibitor (Kunitz) in various bovine organs. Jan 17 1983

4/6/121 04461712 83130510

Development and evaluation of an inhibitor-releasing matrix for intrauterine devices. Nov 1982

4/6/122 04446087 82004641

Mechanism of proteinase complex formation with alpha 2-macroglobulin. Three modes of trypsin binding. Jun 1 1981

4/6/123 04443495 81210133

Suppression of serum or liver cytosol-induced G1-S block in baby rat hepatocytes by a protease antagonist: the Kunitz factor. May 1981

4/6/124 04441901 81164340

Effects of rat urinary arginine esterases on rat kidney to release renin. May 1981

4/6/125 04440787 81129687

Effects of caerulein and trypsin inhibitors on the endocrine mouse pancreas. Feb 1981

4/6/126 04432837 80109693

Thermodynamics and kinetics of the hydrolysis of the reactive-site peptide bond in pancreatic trypsin inhibitor (Kunitz) by Dermasterias imbricata trypsin 1. Jan 8 1980

4/6/127 04176545 83162745

Endothelial injury in scleroderma. A protease mechanism. ...

4/6/128 03273427 80106972

Enterokinase induced pancreatitis: its prevention with Trasylol and soybean trypsin inhibitor. Nov-Dec 1978

4/6/129 03245079 76232412

Human plasma kallikreins and their inhibition by amidino compounds. Jun 7 1976

4/6/130 03240690 76089182

[Effect of trypsin inhibitor of a peptide-protein nature on kallikreins from human and rabbit blood stream] Deistzie Ingibitoroz Tripsina Peptidno-Belkozoi Prirody Na Kallikreiny Cyzorotiki Krozi Chelozeka I Krolika Mar-Apr 1975

4/6/131 03239409 76043681

Trypsin-kallikrein isoinhibitor K (type Kunitz) from snails (Helix pomatia). Purification and characterization. Oct 15 1975

4/6/132 03120797 80085538

The inhibition of corneal vascularization with aortic extracts in rabbits. Dec 1979

4/6/133 03106283 78149674

The elimination in dogs of trypsin-alpha-macroglobulin complexes inactivated by the Kazal or the Kunitz inhibitor. Mar 1978

4/6/134 03064036 78190646

Kinetics of the interaction of alpha-chymotrypsin with trypsin kallikrein inhibitor (Kunitz) in which the reactive-site peptide bond Lys-15--Ala-16 is split. May 16 1978

4/6/135 03063876 78187270

Stopped-flow kinetics of the resynthesis of the reactive site peptile bond in kallikrein inhibitor (Kunitz) by beta-trypsin. May 2 1978

4/6/136 03051048 77050085

Influence of various fluorescent and non-fluorescent labels on the kinetics of the complex formation of alpha-chymotrypsin with basic pancreatic trypsin inhibitor (Kunitz). Sep 1976

4/6/137 03044497 76141310

[The disulfide bridges of the trypsin-kallikrein inhibitor K from snails (Helix pomatia). Thermal inactivation and proteolysis by thermolysin (author's transl)] Die Disulfidbrucken des Trypsin-Kallikrein-Inhibitors K aus Weinbergschnecken (Helix pomatia). Thermische Denaturierung und thermolysinolytische Inaktivierung Feb 1976

4/6/138 03038590 75209019

The reactive sites of Kunitz bovine-trypsin inhibitor. Role of lysine-15 in the interaction with chymotrypsin. May 1975

4/6/139 02825259 78101904

The disintegration of surgical sutures on exposure to pancreatic juice. Dec 1977

4/6/140 02823083 77248645

Arginine modification in Kunitz bovine trypsin inhibitor through 1, 2-cyclohexanedione. 1977

4/6/141 02821669 77157777

Synthesis and characterization of a pancreatic trypsin inhibitor homologue and a model inhibitor. Apr 19 1977

4/6/142 0242... 77095187

Trypsin ... with soluble ela... Conformation-directed proteolysis of Ku... 20.

4/6/144 02291254 ...

...pressor and plasma kininogen changes towards acute adrenaline pulmonary edema in the rat. Nov 1976

4/6/145 02290683 77030863

Studies on the solid-phase synthesis of bovine pancreatic trypsin inhibitor (Kunitz) and the characterization of the synthetic material. Aug 20 1976

4/6/146 02288830 76210976

Interaction of clostripain with natural trypsin inhibitors and its affinity labeling by Nalpha-p-nitrobenzyloxycarbonyl arginine chlormethyl ketone. Jul 1 1976

4/6/147 02287126 76119529

Synthesis and biological activity of some cystine peptides from the active center of the basic trypsin inhibitor from bovine organs (Kunitz inhibitor) (author's transl)] Synthese und biologische Aktivatat von Cystinpeptiden aus dem aktiven Zentrum des basischen Trypsininhibitors aus Rinderorganen (Kunitz -Inhibitor) Oct 1975

4/6/148 02285130 75210728

Partial purification and properties of cathepsin D in the retinal pigment epithelium. Aug 1975

4/6/149 02284802 75186882

The two human trypsinogens. Inhibition spectra of the two human trypsins derived from their purified zymogens. May 6 1975

4/6/150 02284024 75119072

In vivo interaction of the Kunitz protease inhibitor and of insulin with subcellular structures from rat renal cortex. 1975

4/6/151 01976943 73024375

The isolation of porcine and human kallikrein using affinity chromatography: specific binding to water-insoluble Kunitz soyb inhibitor-celluloses and dissociation with competitive inhibitors (benzamid Zur Isolierung von Schweine- und Human-Serumkallikren durch Affinitatschromatographie. Spezifische Bindung an wasserunlosliche Kun Sojabohnen-Inhibitor-Cellulosen und dissoziation mit kompetitiven Hemmstoffen (Benzamidin. Jun 1972

4/6/152 01527955 75052888

Inactivation of the trypsin-kallikrein inhibitor (Kunitz) by cleavage of the dipeptide Ala 16--Arg 17 in the reactive site. Oct 1974

4/6/153 01527954 75052887

Replacement of lysine by arginine, phenylalanine, and tryptophan ... reactive site of the trypsin-kallikrein inhibitor (Kunitz) Oct 1974

4/6/154 01527953 75052886

Proteinase catalyzed resynthesis of the pepti... zur derivative of trypsin-kallikrein inhibitor (K... hydrolyzed. Oct 1974

4/6/155 01527952 75...

Synthesis of the ... with open pe...

...(R) (c) format only 2000 Dialog

...3318

...of secreted Kunitz domain 1 variants of tissue factor pathway inhibitor.

Johnson K; Zaror I; Bauer D; Choi Y; Creasey A; Innis M

Chiron Technologies, Chiron Corporation, Emeryville, CA 94608, USA.

Thrombosis and haemostasis (GERMANY) Oct 1998, 80 (4) p585-7, ISSN 0340-6245 Journal Code: VQ7 Languages ENGLISH Document type: JOURNAL ARTICLE JOURNAL ANNOUNCEMENT: 9903 Subfile: INDEX MEDICUS

Tissue factor pathway inhibitors (TFPI and TFPI-2) are Kur domain-type serine protease inhibitors which inhibit factor VIIa/tissue factor (VIIa/TF) complexes in a factor Xa-dependent manner. The VIIa/TF and Xa inhibitory activity has been locali to the first two Kunitz domains, respectively. Unlike TFPI, TF has been reported to exhibit significant Xa-independent VIIa/TF inhibitory activity, perhaps due to an arginine at the P1 residu the first Kunitz domain of TFPI-2 as opposed to a lysine at comparable residue in TFPI. Two domain TFPI variants, differ the first Kunitz domain but containing the second Kunitz do of TFPI, were constructed and secreted by Saccharomyces cerevisiae in order to test the possibility that a TFPI first K domain with a P1 lysine to arginine change or a hybrid co the TFPI-2 first Kunitz domain may represent more potent inhibitors. When yeast supernatants were analyzed ... activity in the Xa-dependent inhibition of VIIa/TF, ... was as active as the truncated TFPI.

Tags: Human

10/6/20 10098106 98153773
Role of O-linked carbohydrate of human urinary trypsin inhibitor on its lysosomal membrane-stabilizing property. Feb 13 1998

10/6/21 10090168 98010584
Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor. Oct 31 1997

10/6/22 10085470 97408608
Inhibition of tryptase TL2 from human T4+ lymphocytes and inhibition of HIV-1 replication in H9 cells by recombinant aprotinin and bikunin homologues. Aug 1997

10/6/23 10074789 97197808
Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. Mar 7 1997

10/6/24 10023996 99394617
Detection of bikunin mRNA in limited portions of rat brain. 1999

10/6/25 09981028 99256693
Inhibitory properties of human recombinant Arg24-->Gln type-2 tissue factor pathway inhibitor (R24Q TFPI-2). May 1 1999

10/6/26 09935428 99259590
Guinea pig alpha 1-microglobulin/bikunin: cDNA sequencing, tissue expression and expression during acute phase. Feb 1999

10/6/27 09808582 99115478
Assembly and secretion of recombinant chains of human inter-alpha-trypsin inhibitor in COS-7 cells. Jan 1999

10/6/28 09757475 99034344
Tissue factor pathway inhibitor gene disruption. Mar 1998

10/6/29 09755682 99062350
[An inhibitor of enteropeptidases and trypsin from the bovine duodenum] Ingibitor enteropeptidazy i tripsina iz dvenadtsatiperstnoi kishki byka. Jul-Aug 1998

10/6/30 09640676 98417592
White matter astrocytes produce hepatocyte growth factor activator inhibitor in human brain tissues. Sep 1998

10/6/31 09608502 98381064
Aptinin, the first competitive protein inhibitor of NOS activity. Aug 10 1998

10/6/32 09608287 98391184
Recombinant Kunitz protease inhibitor ameliorates reperfusion injury in rat lung transplantation. Aug 1998

10/6/33 09600751 98357230
Cytotoxicity induced by Erythrina variegata serine proteinase inhibitors in tumor hematopoietic stem cell lines. Jun 1998

10/6/34 09490683 98258940
Kunitz-type proteinase inhibitors from intact and Phytophthora-infected potato tubers. Apr 10 1998

10/6/35 09486293 98207966
Specific expression of PP5/TFPI2 mRNA by syncytiotrophoblasts in human placenta as revealed by in situ hybridization. Mar-Apr 1998

10/6/36 09478304 98227321
The crystal structure of bikunin from the inter-alpha-inhibitor complex: a serine protease inhibitor with two Kunitz domains. Mar 13 1998

10/6/37 09407434 98128798
Kunitz -type soybean trypsin inhibitor revisited: refined structure of its complex with porcine trypsin reveals an insight into the interaction between a homologous inhibitor from Erythrina caffra and tissue-type plasminogen activator. Jan 16 1998

10/6/38 09383083 98106032
Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2. Jan 1998

10/6/39 09373334 98094245
Cloning of a new Kunitz -type protease inhibitor with a putative transmembrane domain overexpressed in pancreatic cancer. Jan 7 1998

10/6/40 09128394 97277372
Identification and cloning of human placental bikunin, a novel serine protease inhibitor containing two Kunitz domains. May 2 1997

10/6/41 09100907 97196846
Strong crossreaction of human anti-aprotinin antibodies from heart transplant patient with [Arg15]aprotinin. Jan 1997

10/6/42 09059699 97381310
Obtaining a family of high-affinity, high-specificity protein inhibitors of plasmin and plasma kallikrein. Oct 1996

10/6/43 09056084 97103482
Purification and characterization of a novel isoform of mast cell tryptase from rat tongue. Oct 1996

10/6/44 09048106 96388868
Plant serine proteinase inhibitors. Structure and biochemical applications on plasma kallikrein and related enzymes. May 1996

10/6/45 09045979 96337524
Partial purification and characterization of a novel soybean protease which is inhibited by Kunitz and Bowman-Birk trypsin inhibitors. Apr 1996

10/6/46 09042465 96264920
Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin. Jun 18 1996

10/6/47 09011457 97017675
Immunohistochemical localization of tissue factor pathway inhibitor-1 (TFPI-1), a Kunitz proteinase inhibitor, in Alzheimer's disease. Jul 22 1996

10/6/48 09007168 96387211
The disulfide folding pathway of tick anticoagulant peptide (TAP), a Kunitz-type inhibitor structurally homologous to BPTI. Sep 10 1996

10/6/49 08971426 97151513
Purification and characterisation of 6 and 58 kDa forms of the endogenous serine proteinase inhibitory proteins of ovine articular cartilage. Dec 1996

10/6/50 08934843 97141217
Inhibitory potency of Erythrina variegata proteinase inhibitors toward serine proteinases in the blood coagulation and fibrinolytic systems. Aug 1996

10/6/51 08933024 97080691
Serine proteinase inhibitors from insect hemolymph. 1996

10/6/52 08895430 97128614
An evolutionarily conserved binding site for serine proteinase inhibitors in large conductance calcium-activated potassium channels. Dec 17 1996

10/6/53 08827612 96437192
The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor. Jun 1996

10/6/54 08722679 96264919
Iterative optimization of high-affinity proteases inhibitors using phage display. 1. Plasmin. Jun 18 1996

10/6/55 08713178 98298519
Surface expression and ligand-based selection of cDNAs fused to filamentous phage gene VI. Apr 1995

10/6/56 08712458 96431150
Regulation and regulatory role of proteinase inhibitors. 1995

10/6/57 08709132 96202952
Inhibitory properties of separate recombinant Kunitz -type-protease-inhibitor domains from tissue-factor-pathway inhibitor. Jan 15 1996

10/6/58 08705507 96134844
Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Jan 9 1996

10/6/59 08699724 96029621
Potent and selective Kunitz domain inhibitors of plasma kallikrein designed by phage display. Oct 27 1995

10/6/60 08680072 95050516
Characterization of the serine protease and serine protease inhibitor from the tissue-penetrating nematode Anisakis simplex. Nov 4 1994

10/6/61 08667116 94119575
Interaction of hepatitis B virus X protein with a serine protease, tryptase TL2 as an inhibitor. Feb 1994

10/6/62 08651181 96217894
Thermodynamic stability effects of single peptide bond hydrolysis in protein inhibitors of serine proteinases. Mar 8 1996

10/6/63 08629283 96182215
Genetically engineered serine protease inhibitor for hemostasis after cardiac operations. Apr 1996

10/6/64 08573519 95244502
Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: a segment, Gly212-Phe243, of the third Kunitz domain is a heparin-binding site. May 2 1995

10/6/65 08537879 96360459
Characterisation of a novel Kunitz-type molecule from the trematode Fasciola hepatica. Oct 1995

10/6/66 08521136 96263879
Biochemistry and functions of hepatitis B virus X protein. 1995

10/6/67 08502624 96124427
Full-length human tissue factor pathway inhibitor inhibits human activated protein C in the presence of heparin. Nov 15 1995

10/6/68 08433177 96083781
Serine proteinase inhibitors in human skeletal muscle: expression of beta-amyloid protein precursor and alpha 1-antichymotrypsin in vivo and during myogenesis in vitro. Dec 1995

10/6/69 08407341 96032709
Enhanced plasmin inhibition by a reactive center lysine mutant of the Kunitz -type protease inhibitor domain of the amyloid beta-protein precursor. Sep 29 1995

10/6/70 08391875 95276660
NMR structure determination of tick anticoagulant peptide (TAP). Feb 1995

10/6/71 08364623 95375152
Tissue factor pathway inhibitor and the current concept of blood coagulation. Jun 1995

10/6/72 08333426 95329572
Effect of repeated Aprosulate and Enoxaparin administration on tissue factor pathway inhibitor antigen levels. Apr 1995

10/6/73 08266226 95221631
The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. Apr 1995

10/6/74 08171502 95110820
Sequencing of cDNAs encoding alpha 1-microglobulin/bikunin of Mongolian gerbil and Syrian golden hamster in comparison with man and other species. Dec 14 1994

10/6/75 08163479 94294439
The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor. Jul 5 1994

10/6/76 08158781 94171738
Selective cloning of cDNA for secretory proteins of early embryos. Identification of a transiently expressed kunitz domain protein from preimplantation sheep trophoblast. Mar 11 1994

10/6/77 08134687 95204397
cDNA cloning and mRNA expression of a serine proteinase inhibitor secreted by cancer cells: identification as placental protein 5 and tissue factor [illegible]way inhibitor-2. Nov 1994

[illegible]/78 07861535 94076343
Affinity and specificity of serine endopeptidase-protein inhibitor interactions. Empirical free energy calculations based on X-ray crystallographic structures. Dec 5 1993

10/6/79 07850240 93218097
[Mechanism of hepatocarcinogenesis by hepatitis B virus] Feb 1993

10/6/80 07848799 93183487
Interaction of human mast cell tryptase and chymase with low-molecular-mass serine proteinase inhibitors from the human respiratory tract. 1993

10/6/81 07796209 93164867
Increased levels of the Kunitz protease inhibitor-containing beta APP mRNAs in rat brain following neurotoxic damage. Jan 1993

10/6/82 07769743 94146152
Inhibitory spectra of purified protease nexin-II and related proteins towards cellular proteinases. 1993

10/6/83 07634501 93350188
beta-Amyloid precursor protein mRNA is increased in inclusion-body [illegible]itis muscle. Jun 1993

[illegible]/84 07572741 93305673
Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). Jul 1993

10/6/85 07527786 93226083
Differential regional and cellular distribution of beta-amyloid precursor protein messenger RNAs containing and lacking the Kunitz protease inhibitor domain in the brain of human, rat and mouse. Mar 1993

10/6/86 07455331 91310622
Determination of disulfide bond pairs and stability in recombinant tick [illegible]nticoagulant peptide. Jul 25 1991

[illegible]0/6/87 07279545 93113091
[illegible]olation and primary structure of proteinase inhibitors from Erythrina [illegible]riegata (Linn.) var. Orientalis seeds. Nov 1992

[illegible]/6/88 06975949 92031488
[illegible]equential NMR resonance assignment and structure determination of the [illegible]itz -type inhibitor domain of the Alzheimer's beta-amyloid precursor [illegible]ein. Oct 29 1991

10/6/89 06950358 92198402
A novel membrane-bound serine esterase in human T4(+)-lymphocytes is a binding protein of envelope glycoprotein gp120 of HIV-1. 1991

10/6/90 06597448 91115653
X protein of hepatitis B virus resembles a serine protease inhibitor. Dec 1990

10/6/91 06585980 90260664
Platelet coagulation factor XIa-inhibitor, a form of Alzheimer amyloid precursor protein. Jun 1 1990

10/6/92 06525799 91085579
Purification and characterization of a chymotrypsin Kunitz inhibitor type of polypeptide from the venom of cobra (Naja naja naja). Nov 26 1990

10/6/93 06388749 90239551
Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa [published erratum appears in Science 1990 Jun 22;248(4962):1473] May 4 1990

10/6/94 06247269 90044496 Novel therapy for Alzheimer's disease. Sep-Oct 1989

10/7/71 DIALOG(R)File 155:MEDLINE(R) (c) format only 2000 Dialog Corporation. All rts. reserv.
08364623 95375152
Tissue factor pathway inhibitor and the current concept of blood coagulation.
Broze GJ Jr
Division of Hematology/Oncology, Jewish Hospital, Washington University Medical Center, St Louis, MO 63110, USA.
Blood coagulation & fibrinolysis (ENGLAND) Jun 1995, 6 Suppl 1 pS7-13, ISSN 0957-5235 Journal Code: A5J Contract/Grant No.: HL34462, HL, NHLBI; HL14147, HL, NHLBI Languages: ENGLISH Document type:JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
Tissue factor pathway inhibitor (TFPI) is a multivalent, Kunitz – type plasma proteinase inhibitor that regulates tissue factor-induced coagulation. TFPI directly inhibits activated factor X and, in a factor Xa-dependent manner, produces feedback inhibition of the factor VIIa/tissue factor catalytic complex. The properties of this inhibitor help explain the clinical need for 'extrinsic' and 'intrinsic' coagulation pathways and have led to a reformulation of the coagulation cascade. In the revised hypothesis, factor VIIa/tissue factor is responsible for the initiation of coagulation but, owing to TFPI-mediated feedback inhibition, amplification of the procoagulant response though the actions of factor VIII, IX and XI is required for sustained haemostasis. (40 Refs.)

10/7/63 DIALOG(R)File 155:MEDLINE(R) (c) format only 2000 Dialog Corporation. All rts. reserv.
08629283 96182215
Genetically engineered serine protease inhibitor for hemostasis after cardiac operations.
Ohri SK; Paratt R; Becket JM; Brannan J; Hunt BJ; Taylor KM
Cardiothoracic Unit, Department of Surgery, Royal Postgraduate Medical School, Hammersmith Hospital, London, England.
Annals of thoracic surgery (UNITED STATES) Apr 1996, 61 (4) p1223-30 ISSN 0003-4975 Journal Code: 683 Languages: ENGLISH Document type: JOURNAL ARTICLE
BACKGROUND: The serine protease inhibitor aprotinin has been widely reported for its beneficial action in limiting blood loss after cardiopulmonary bypass (CPB). A potent human serine protease inhibitor known as protease nexin II or amyloid precursor protein has been recently isolated. A recombinant protein known as recombinant Kunitz protease inhibitor (rKPI; Scios Nova Mountain View, CA) with sequence homology to the protease nexin II-amyloid precursor protein molecule has been manufactured METHODS: Recombinant Kunitz protease inhibitor was assessed in an ovine model of CPB as a hemostatic agent after CPB. Sheep (n = 22) underwent CPB for 90 minutes. Two thoracic drains were sited and drain losses collected for a period of 3 hours after CPB. Wounds were subjectively assessed before closure for "dryness" using a visual analogue scale. Sheep were randomized to control (n = 8), aprotinin (n = 8), and rKPI (n = 6) groups. RESULTS: Control animals had a drain loss of 409.4 +/- 39.4 mL/3 h, compared with 131.3 +/- 20.3 mL/3 h for the aprotinin group and 163.7 +/- 34.3 mL/3 h for the rKPI group (p = 0.16). Hemoglobin loss was 11.6 +/- 3.6, 6.02 +/- 2.1, and 4.6 +/- 1.2 g/3 h for the control, rKPI, and aprotinin groups respectively (p = 0.25). The subjective analysis of the wounds at the end of CPB found aprotinin (1.25 +/- 0.16; p < 0.05) and rKPI (1.17 +/- 0.17; p < 0.05) animals to score significantly lower than control animals (2.63 +/- 0.42). CONCLUSIONS: On the basis of these in vivo findings, genetic modification may yield a more efficacious serine protease inhibitor with the inherent advantages of using a human-based protein.

10/5/57 DIALOG(R)File 155:MEDLINE(R) (c) format only 2000 Dialog Corporation. All rts. reserv.
08709132 96202952
Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor.
Petersen LC; Bjorn SE; Olsen OH; Nordfang O; Norris F; Norris K
Health Care Discovery, Vessel Wall Biology, Novo Nordisk A/S, Gentofte, Denmark.
European journal of biochemistry (GERMANY) Jan 15 1996, 235 (1-2) p310-6, ISSN 0014-2956 Journal Code: EMZ
Languages: ENGLISH Document type: JOURNAL ARTICLE
JOURNAL ANNOUNCEMENT: 9609 Subfile: INDEX MEDICUS
Tissue-factor-pathway inhibitor (TFPI) is a multivalent inhibitor with three tandemly arranged Kunitz-type-protease-inhibitor (KPI) domains. Previous studies [Girard, Y. J., Warren, L. A., Novotny, W. F., Likert, K. M., Brown, S. G., Miletich, J. R & Broze, G. J. (1989) Nature 338, 518-520] by means of site-directed mutagenesis indicated that KPI domain 1 interacts with factor VIIa, that KPI domain 2 interacts with factor Xa, and that KPI domain 3 is apparently without inhibitory function. To elucidate thereaction mechanism of this complex inhibitor, we followed a different approach and studied the inhibitory properties of fragments of TFPI obtained by expression in yeast. Results obtained with TFPI-(1-161)-peptide and separate recombinant TFPI-KPI domains 1, 2 and 3 showed that KPI domain 1 inhibited factor VIIa/tissue factor (Ki = 250 nM), KPI domain 2 inhibited factor Xa (Ki = 90 nM), and that KPI domain 3 was without detectable inhibitory function. Studies with separate KPI domains also showed that KPI domain 2 was mainly responsible for inhibition of trypsin (Ki = 0.1 nM) and chymotrypsin (Ki = 0.75 nM), whereas KPI domain 1 inhibited plasmin (Ki = 26 nM) and cathepsin G (Ki = 200 nM). The structural basis for the interaction between serine proteases and KPI domains is discussed in terms of putative three-dimensional models of the proteins derived by comparative molecular-modelling methods. Studies of factor Xa inhibition by intact TFPI (Ki approximately 0.02 nM) suggested that regions other than the contact area of the KPI domain, interacted strongly with factor Xa. Secondary-site interactions were crucial for TFPI inhibition of factor Xa but was of little or no importance for its inhibition of trypsin.
Tags: Animal, Human, In Vitro

Descriptors: Lipoproteins--Genetics--GE; *Recombinant Proteins --Pharmacology--PD; *Serine Proteinase Inhibitors--Genetics--GE; *Serine Proteinase Inhibitors--Pharmacology--PD; *Trypsin Inhibitor, Kunitz Soybean--Genetics--GE; *Trypsin nhibitor, Kunitz Soybean—Pharmacology --PD; Amino Acid Sequence; Base Sequence; Binding Sites--Genetics--GE; Cathepsins--Antagonists and Inhibitors--AI; Cell Line; Chymotrypsin --Antagonists and Inhibitors--AI; DNA Primers--Genetics--GE; Factor VIIa --Antagonists and Inhibitors--AI; Factor Xa-Antagonists and Inhibitors—AI ; Hamsters; Kinetics; Models, Molecular; Molecular Sequence Data; Molecular Structure; Pancreatic Elastase--Antagonists and Inhibitors--AI; Plasmin --Antagonists and Inhibitors--AI; Protein Conformation; Recombinant Proteins--Chemistry--CH; Recombinant Proteins--Genetics--GE; Saccharomyces cerevisiae--Genetics--GE; Serine Proteinase Inhibitors--Chemistry--CH; Trypsin Inhibitor, Kunitz Soybean--Chemistry--CH

[redacted] Registry No.: 0 (lipoprotein-associated coagulation inhibitor); [redacted]A Primers); 0 (Lipoproteins); 0 (Recombinant Proteins); 0 Serine Proteinase Inhibitors); 9088-41-9 (Trypsin Inhibitor, Kunitz Soybean) Enzyme No.: EC 3.4.- (Cathepsins); EC 3.4.21.1 Chymotrypsin); EC 3.4.21.20 (cathepsin G); EC 3.4.21.21 Factor VIIa); EC 3.4.21.36 (Pancreatic Elastase); EC 3.4.21.6 Factor Xa); EC 3.4.21.7 (Plasmin)

7/6/1 10447148 20279908
Apical and non-polarized secretion of serpins from MDCK cells. May 19 2000

7/6/2 10385048 20243880
Structural basis for selectivity of a small molecule, S1-binding, ubmicromolar inhibitor of urokinase-type plasminogen activator. Apr 2000

7/6/3 09554958 98316623
dentification of Man alpha1-3Man alpha1-2Man and Man-linked phosphate on -mannosylated recombinant leech-derived tryptase inhibitor produced by accharomyces cerevisiae and determination of the solution conformation of e mannosylated polypeptide. May 1 1998

7/6/4 09513564 98272266
HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by e matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI. May 29

[redacted]

7/6/5 09166153 97297135
iodistribution and pharmacokinetics of 131I-labeled LEX 032, a combinant hybrid of antichymotrypsin. May 1997

7/6/6 09054517 97075037
urification, characterization and biological evaluation of recombinant leech-rived tryptase inhibitor (rLDTI) expressed at high level in the yeast accharomyces cerevisiae. Oct 15 1996

7/6/7 09053134 97049917
ecombinant human insulin-like growth factor (IGF) binding protein-3 mulates prostate carcinoma cell proliferation via an IGF-dependent echanism. Role of serine proteases. Sep 1996

7/6/8 08895509 97135088
he inhibition of human factor Xa by plasminogen activator inhibitor type 1 in e presence of calcium ion, and its enhancement by heparin and ronectin. Dec 5 1996

7/6/9 08864765 97072004
xtracellular matrix-associated serine protease inhibitors (Mr 33,000, 31,000, d 27,000) are single-gene products with differential glycosylation : NA cloning of the 33-kDa inhibitor reveals its identity tissue factor pathway inhibitor-2. Nov 1 1996

17/6/10 07805241 94043294
Kallistatin: a novel human serine proteinase inhibitor. Molecular cloning, tissue distribution, and expression in Escherichia coli. Nov 15 1993

17/7/8 DIALOG(R)File 155:MEDLINE(R) (c) format only 2000 Dialog Corporation. All rts. reserv.
08895509 97135088
The inhibition of human factor Xa by plasminogen activator inhibitor type 1 in the presence of calcium ion, and its enhancement by heparin and vitronectin.
Urano T; Ihara H; Takada Y; Nagai N; Takada A
Department of Physiology, Hamamatsu University School of Medicine, Shizuoka, Japan.
Biochimica et biophysica acta (NETHERLANDS) Dec 5 1996, 1298 (2) p199-208, ISSN 0006-3002 Journal Code: A0W
Languages: ENGLISH Document type: JOURNAL ARTICLE
Plasminogen activator inhibitor type 1 (PAI-1), a member of serine proteinase inhibitor superfamily, is known to inhibit thrombin in the presence of either heparin or vitronectin. We analyzed possible inhibitory activity of PAI-1 on human factor Xa. PAI-1 inhibited factor Xa in the presence of calcium ion (Ca2+), whereas no inhibition was observed in the absence of Ca2+. Half maximal enhancement by Ca2+ was obtained at 0.8 mM. An equimolar complex formation between factor Xa and PAI-1 in the presence of Ca2+ was observed by SDS polyacrylamide gel electrophoresis. Both unfractionated heparin and vitronectin enhanced the inhibition only in the presence of Ca2+. Apparent second-order rate constant (ki) for the inhibition of factor Xa by PAI-1 at 5 mM Ca2+ was 1.6 x 10(4) M-1 s-1, and was enhanced 3-fold by 2 u/ml of heparin (4.6 x 10(4) M-1 s-1) and 10-fold by 100 nM vitronectin (1.6 x 10(5) M-1 s-1), respectively. The interaction between Ca(2+)-bound factor Xa and PAI-1 could be important from the view of PAI-1 neutralization and enhancement of fibrinolysis.

17/7/9 DIALOG(R)File 155:MEDLINE(R) (c) format only 2000 Dialog Corporation. All rts. reserv.
08864765 97072004
Extracellular matrix-associated serine protease inhibitors (Mr 33,000, 31,000, and 27,000) are single-gene products with differential glycosylation : cDNA cloning of the 33-kDa inhibitor reveals its identity to tissue factor pathway inhibitor-2.
Rao CN; Reddy P; Liu Y; O'Toole E; Reeder D; oster DC; Kisiel W; Woodley DT
Department of Dermatology, Northwestern University School of Medicine, Chicago, Illinois 60611-3008, USA.
Archives of biochemistry and biophysics (UNITED STATES) Nov 1 1996, 335 (1) p82-92, ISSN 0003-9861 Journal Code: 6SK
Contract/Grant No.: AR 41045, AR, NIAMS; AR 33625, AR, NIAMS; HL 35246, HL, NHLBI Languages: ENGLISH Document type: JOURNAL ARTICLE
Recently, we reported the identification and partial characterization of three serine protease inhibitors (M(r) 33,000, 31,000, and 27,000) from the extracellular matrix (ECM) of human umbilical vein endothelial cells and skin cells. Here, we report that a full-length cDNA clone for the 33-kDa inhibitor from SV-40 transformed human skin fibroblasts (t12FB) is identical to a recombinant trypsin/tissue factor pathway inhibitor called TFPI-2 from placenta. By immunoblotting, the three inhibitors from ECM and cell lysates demonstrated cross-reactivity with an antiTFPI-2 IgG. To further elucidate how these inhibitors are related, pulse-chase labeling of t12FB with [35S]methionine followed by immunoprecipitation with antiTFPI-2 IgG was performed on ECM and cytosolic proteins. A precursor-product relationship did not exist between the three inhibitors from ECM. In contrast, the various species of inhibitors from cytosolic fractions demonstrated a precursor-product relationship. Within the cytosolic fraction, 26-, 29-, and 30-kDa inhibitors were detected in the early chases (0 and 15 min) but they form precursors to the synthesis of the 33-kDa inhibitor which accumulated in the later chases (30 min to 1 h). When pulse-chase experiments were performed in the presence of tunicamycin, synthesis as well as sequestration of the three inhibitors into ECM was completely inhibited. In the presence of tunicamycin, the cells synthesized and sequestered a single 25.5-kDa inhibitor into ECM. Peak quantities of the 25.5-kDa inhibitor appeared in the ECM after 6 h chase while they were 1 h for the 27- and 31-kDa inhibitors and 3 h for the 33-kDa inhibitor. To further support that the three inhibitors are related but only differ in the extent of glycosylation , the 33-kDa inhibitor from the t12FB ECM was deglycosylated with N-glycosidase F and the products were identified by immunoblotting with antiTFPI-2 IgG. The enzyme released the 31-, 27-, and 25.5-kDa inhibitors from the 33-kDa inhibitor. Collectively, these results demonstrate that the ECM-associated 33-, 31-, and 27-kDa inhibitors are biosynthetic products of a single gene with differential glycosylation . The 25.5-kDa inhibitor is unglycosylated, whereas 27- and 30- to 31-kDa inhibitors are partially glycosylated and the 33-kDa inhibitor is fully glycosylated . Inhibition of glycosylation significantly retarded the rate of secretion of the inhibitor but did not prevent its association with ECM. Quantitation of the inhibitors with cell-conditioned medium and ECM fractions reveals that 70-75% were ECM-associated and 25-30% cell-associated. None or very little of the inhibitors (0-2%) remained in a conditioned medium. Because they are primarily associated with ECM, the inhibitors may play a major role in ECM remodeling and turnover.

19/6/1 10384687 20177994
Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor. Mar 2000

20/6/1 10572466 20420411
Mutation of any site of N-linked glycosylation accelerates the in vivo clearance of recombinant rabbit antithrombin. Aug 15 2000

20/6/2 10472170 20262971
Subcutaneous administration of recombinant glycosylated interleukin 6 in patients with cancer: pharmacokinetics, pharmacodynamics and immunomodulatory effects. Apr 2000

20/6/3 10467832 20318645
The N-glycans determine the differential blood clearance and hepatic uptake of human immunoglobulin (Ig)A1 and IgA2 isotypes. Jun 19 2000

20/6/4 10429829 20263631
O- glycosylation delays the clearance of human IGF-binding protein-6 from the circulation. May 2000

20/6/5 10369730 20192791
Insulin glargine. Feb 2000

20/6/6 10367142 20209710
Efficacy of a new formulation of lenograstim (recombinant glycosylated human granulocyte colony-stimulating factor) containing gelatin for the treatment of neutropenia after consolidation chemotherapy in patients with acute myeloid leukemia. Feb 2000

20/6/7 10238294 20086111
Influence of glycosylation on the clearance of recombinant human sex hormone-binding globulin from rabbit blood. Sep-Oct 1999

20/6/8 10214323 20042784
Newer thrombolytic agents. May 1999

20/6/9 10075654 97217420
Production and characterization of recombinant active mouse gelatinase B from eukaryotic cells and in vivo effects after intravenous administration. Feb 15 1997

20/6/10 10072640 97135824
Structure-function studies on human macrophage colony-stimulating factor (M-CSF). Jan 1997

20/6/11 09917284 99233290
Pharmacokinetics of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) in healthy male volunteers. Mar 1999

20/6/12 09783988 99035295
A phase I trial of a new recombinant human beta-interferon (BG9015) for the treatment of patients with recurrent gliomas. Mar 1997

20/6/13 09653694 98011759
Intracellular transport, cell-surface exposure and release of recombinant Tamm-Horsfall glycoprotein. Nov 1997

[redacted]/14 09400782 98118520
[redacted] of oligosaccharides in the pharmacokinetics of tissue-derived and genetically engineered cholinesterases. Jan 1998

20/6/15 09225154 97410238
Crossover study of the haematological effects and pharmacokinetics of glycosylated and non- glycosylated G-CSF in healthy volunteers. Aug 1997

20/6/16 09205476 97338576
Three types of recombinant human granulocyte colony-stimulating factor have equivalent biological activities in monkeys. May 1997

20/6/17 09196837 97368045
Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Jul 1997

20/6/18 09193165 97364416
Pharmacokinetic studies of intravenous glycosylated recombinant human granulocyte colony-stimulating factor in various hematological disorders: inverse correlation between the half-life and bone marrow myeloid cell pool. Jul 1997

20/6/19 09166153 97297135
Biodistribution and pharmacokinetics of 131I-labeled LEX 032, a recombinant hybrid of antichymotrypsin. May 1997

[redacted]/20 08986171 97012791
D-mannose dimer introduced human recombinant interleukin- 1 alpha, NEO -1 alpha, exhibits altered tissue distribution in mice. Apr 1996

0/6/21 08757629 96303248
apid clearance of human insulin-like growth factor binding protein-3 from e rat circulation and cellular localization in liver, kidney and stomach. Mar 996

0/6/22 08687940 95207991
harmacokinetics and pharmacodynamics of saruplase, an unglycosylated ngle-chain urokinase-type plasminogen activator, in patients with acute ocardial infarction. Nov 1994

)/6/23 08585752 96027660
harmacokinetic and pharmacodynamic studies of subcutaneously ministered recombinant human interleukin-3 following chemotherapy for n-Hodgkin's lymphoma. Oct 1995

/6/24 08481390 96148605
pression of recombinant soluble Fc epsilon RI: function and tissue tribution studies. Nov 1995

20/6/25 08329442 95323952
An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models. May 1995

20/6/26 08223280 95258970
In vitro stability of a tissue-type plasminogen activator mutant, BM 06.022, in human plasma. Dec 1994

20/6/27 08174157 95209927
The optimal dose of glycosylated recombinant human granulocyte colony stimulating factor for use in clinical practice: a review. 1994

20/6/28 08169151 95050408
Modification of recombinant human granulocyte colony-stimulating factor (rhG-CSF) and its derivative ND 28 with polyethylene glycol. May 1994

20/6/29 08162234 94264694
Manipula tion of renal disposition of human recombinant superoxide dismutase by chemical modification. Feb 1994

20/6/30 08150166 94242352
Glycosylation of recombinant proteins: problems and prospects. May 1994

20/6/31 07847903 93152841
Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase. Feb 1 1993

20/6/32 07791013 94089944
Elimination of radiolabelled recombinant human insulin-like growth factor binding protein-3 from the circulation, and its distribution amongst organs and tissues in adult male rats. Oct 20 1993

20/6/33 07781340 93250519
Properties of glycosylated and non- glycosylated human recombinant IGF binding protein-3 (IGFBP-3). Mar 1993

20/6/34 07666952 94044951
Effect of carbohydrates on the pharmacokinetics of human interferon-gamma. Aug 1993

20/6/35 07628413 93229738
Differential activation of the endogenous leukotriene biosynthesis by two different preparations of granulocyte-macrophage colony-stimulating factor in healthy volunteers. Apr 15 1993

20/6/36 07576759 93311995
N-linked sugar chain structure of recombinant human lymphotoxin produced by CHO cells: the functional role of carbohydrate as to its lectin-like character and clearance velocity. Jul 1993

20/6/37 07518393 93208841
Clinical properties of yeast-derived versus Escherichia coli-derived granulocyte-macrophage colony-stimulating factor. Jan-Feb 1993

20/6/38 07500300 93170458
Comparative pharmacokinetics of single-dose administration of mammalian and bacterially-derived recombinant human granulocyte-macrophage colony-stimulating factor. Jan 1993

20/6/39 07463545 92124438
igh sialic acid content slows prourokinase turnover in rabbits. Jul 15 1991

20/6/40 07397891 93024958
Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli. Jul 1992

20/6/41 07352623 91099165
Biological activity and metabolic clearance of a recombinant human thyrotropin produced in Chinese hamster ovary cells. Jan 1991

20/6/42 07345379 90362851
Pharmacokinetics and coronary thrombolytic properties of two human tissue-type plasminogen activator variants lacking the finger-like, growth factor-like, and first kringle domains (amino acids 6-173) in a canine model. Aug 1990

20/6/43 07192074 93108351
Targeted delivery of human recombinant superoxide dismutase by chemical modification with mono- and polysaccharide derivatives. Dec 1992

20/6/44 07186826 93098795
A non- glycosylated extracellular superoxide dismutase variant. Dec 1 1992

20/6/45 07081976 92346621
Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant. 1992

20/6/46 07048016 92285249
Pharmacokinetics and administration of colony-stimulating factors. 1992

20/6/47 07042777 92275061
In vivo kinetics of 111indium-labelled autologous granulocytes following i.v. administration of granulocyte-macrophage colony-stimulating factor (GM-CSF). Apr 1992

20/6/48 07000498 92178230
Blood clearance in the rat of a recombinant mouse monoclonal antibody lacking the N-linked oligosaccharide side chains of the CH2 domains. Feb 1992

20/6/49 06834835 92090115
Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Dec 1991

20/6/50 06771608 91378352
Purification and characterization of three forms of differently glycosylated recombinant human granulocyte-macrophage colony-stimulating factor. May 1 1991

20/6/51 06610706 90305379
The variability of the absorption of subcutaneously injected insulin: effect of injection technique and relation with brittleness. Jul 1990

20/6/52 06562781 91193873
The pharmacokinetic pattern of glycosylated human recombinant lymphotoxin (LT) in rats after intravenous administration. Sep 1990

20/6/53 06471478 90335258
The role of carbohydrate in the function of human plasminogen: comparison of the protein obtained from molecular cloning and expression in Escherichia coli and COS cells. Jul 6 1990

20/6/54 06235393 89229426
Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat. May 15 1989

20/6/55 06228954 89114703
The influence of carbohydrate structure on the clearance of recombinant tissue-type plasminogen activator. Oct 31 1988

20/6/56 06207273 88078368
Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. Jan 1988

20/6/57 06142688 89088566
Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Jan 1989

20/6/58 05652462 90184773

Blood clearance in the mouse of an aglycosyl recombinant monoclonal antibody. Dec 1989

20/7/26 DIALOG(R)File 155:MEDLINE(R) (c) format only 2000 Dialog Corporation. All rts. reserv.
08223280 95258970
In vitro stability of a tissue-type plasminogen activator mutant, BM 06.022, in human plasma.
Rijken DC; Groeneveld E; Barrett-Bergshoeff MM
Gaubius Laboratory, TNO-PG, Leiden, The Netherlands.
Thrombosis and haemostasis (GERMANY) Dec 1994, 72 (6) p906-11, ISSN 0340-6245 Journal Code: VQ7 Languages: ENGLISH Document type: JOURNAL ARTICLE
BM 06.022 is a non-glycosylated mutant of human tissue-type plasminogen activator (t-PA) comprising only the kringle-2 and proteinase domains. The in vivo half-life of BM 06.022 antigen is 4- to 5-fold longer than that of t-PA antigen. The in vitro half-life of the activity of BM 06.022 at therapeutic concentrations in plasma is [illegible]ter than that of t-PA. In this study the inactivation of BM 06.022 [illegible]sma was further investigated. Varying concentrations of BM 06.022 were incubated in plasma for 0-150 min. Activity assays on serial samples showed a dose-dependent decline of BM 06.022 activity with a half-life from 72 min at 0.3 microgram/ml to 38 min at 10 micrograms/ml. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) followed by fibrin autography showed the generation of several BM 06.022-complexes. These complexes could be completely precipitated with antibodies against CI-inactivator, alpha 2-antiplasmin and alpha 1-antitrypsin. During the incubation of BM 06.022 in plasma, plasmin was generated dose-dependently as revealed by varying degrees of alpha 2-antiplasmin consumption and fibrinogen degradation. SDS-PAGE and immunoblotting showed that single-chain BM 06.022 was rapidly (i.e. within 45 min) converted into its two-chain form at concentrations of 5 micrograms/ml BM 06.022 and higher. In conclusion, BM 06.022 at therapeutic concentrations in plasma was inactivated by CI-inactivator, alpha 2-antiplasmin and alpha 1-antitrypsin.(ABSTRACT TRUNCATED AT 250 WORDS)

20/7/30 DIALOG(R)File 155:MEDLINE(R) (c) format only 2000 Dialog Corporation. All rts. reserv.
[illegible]50166 94242352
[illegible]ycosylation of recombinant proteins: problems and prospects.
Jenkins N; Curling EM
Research School of Biosciences, University of Kent, Canterbury, UK.
Enzyme and microbial technology (ENGLAND) May 1994, 16 (5) 354-64, ISSN 0141-0229 Journal Code: AL3 Languages: ENGLISH Document type: JOURNAL ARTICLE; REVIEW; REVIEW, ACADEMIC (165 Refs.)

20/7/55 DIALOG(R)File 155:MEDLINE(R) (c) format only 2000 Dialog Corporation. All rts. reserv.
08228954 89114703
The influence of carbohydrate structure on the clearance of recombinant tissue-type plasminogen activator.
Rijken DC; Refino CJ; Leonard CK; O'Connor JV; Crowley C; McCabe J; Tate K; Nakamura G; Powers D; Levinson A; et al
Department of Pharmacological Sciences, Genentech, Inc., South San Francisco, CA.
Thrombosis and haemostasis (GERMANY, WEST) Oct 31 1988, 60 (2) p255-61 , ISSN 0340-6245 Journal Code: VQ7 Languages: ENGLISH Document type: JOURNAL ARTICLE

Modification of the carbohydrate structures of recombinant tissue-type plasminogen activator (rt-PA) can increase or decrease its rate of clearance in rabbits. When rt-PA was treated with sodium periodate to oxidize carbohydrate residues, the rate of clearance was decreased from 9.6 +/- 1.9 ml min-1 kg-1 to 3.5 +/- 0.6 ml min-1 kg-1 (mean +/- SD, n = 5). A similar change in the clearance of rt-PA was introduced by the use of endo-beta-N-acetyl-glucosaminidase H (Endo-H), which selectively removes high mannose asparagine-linked oligosaccharides; the clearance of Endo-H-treated rt-PA was 5.0 +/- 0.5 ml min-1 kg-1. A mutant of rt-PA was produced with an amino acid substitution at position 117 (Asn replaced with Gln) to remove a potential glycosylation site that normally contains a high mannose structure. The clearance of this material was also decreased, similar to the periodate and Endo-H-treated rt-PA. Conversely, when rt-PA was produced in the CHO 15B cell line, which can produce only high mannose oligosaccharide structures on glycoproteins, the clearance was increased by a factor of 1.8. These results demonstrate that the removal of rt-PA from the blood depends significantly upon the nature of its oligosaccharide structures.

22/6/1 10568619 20428664
Activation of extracellular-regulated kinase pathways in ovarian granulosa cells by the novel growth factor type 1 follicle-stimulating hormone receptor. Role in hormone signaling and cell proliferation. Sep 8 2000

22/6/2 10530154 20351199
Preparation of recombinant human GDNF by baculovirus expression system and analysis of its biological activities. Jul 14 2000

22/6/3 10476841 20341684
A role for the region encompassing the c" strand of a TCR V alpha domain in T cell activation events. Jul 15 2000

22/6/4 10469564 20330358
4-Aminopyrazolo[3,4-d]pyrimidine (4-APP) as a novel inhibitor of the RNA and DNA depurination induced by Shiga toxin 1. Jun 15 2000

22/6/5 10448102 20287502
The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain. Characterization of interactions and contribution to chemotaxis. Jun 2 2000

22/6/6 10441582 20236063
Effect of lenograstim (glycosylated recombinant human granulocyte-colony stimulating factor) on peripheral blood stem cell mobilization in healthy volunteers] Mar 2000

22/6/7 10428720 20263501
Identification of mutations in rat CD59 that increase the complement regulatory activity. May 16 2000

22/6/8 10424061 20236597
Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings. Mar 2000

22/6/9 10384687 20177994
Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor. Mar 2000

22/6/10 10375547 20153324
Expression, purification, and characterization of human recombinant thrombopoietin in Chinese hamster ovary cells. Mar 2000

22/6/11 10366910 20191472
Molecular cloning and functional analysis of apoxin I, a snake venom-derived apoptosis-inducing factor with L-amino acid oxidase activity. Mar 28 2000

22/6/12 10339913 20200800
In vitro interleukin-13 production by peripheral blood in patients with newly diagnosed insulin-dependent diabetes mellitus and their first degree relatives. Mar 2000

22/6/13 10285621 20107209
Functional and molecular properties of the human recombinant Y4 receptor: resistance to agonist-promoted desensitization. Feb 2000

22/6/14 10273323 20075878
Comparison of lenograstim vs filgrastim administration following chemotherapy for peripheral blood stem cell (PBSC) collection: a retrospective study of 126 patients. Nov 1999

22/6/15 10245616 20025569
Reduction of myocardial infarct size with sCR1sLe(x), an alternatively glycosylated form of human soluble complement receptor type 1 (sCR1), possessing sialyl Lewis x. Nov 1999

22/6/16 10232918 20080264
Estradiol induces and hyperglycosylates the receptor for ovine gonadotropin-releasing hormone. Jan 2000

22/6/17 10225396 20054388
Expression of prolactin and prolactin receptors by non-Hodgkin's lymphoma cells. Jan 1 2000

22/6/18 10198370 20011399
Decreased capacity of recombinant 45/47-kDa molecules (Apa) of Mycobacterium tuberculosis to stimulate T lymphocyte responses related to changes in their mannosylation pattern. Nov 5 1999

22/6/19 10133896 99306568
Paracrine actions of growth differentiation factor-9 in the mammalian ovary. Jun 1999

22/6/20 10131285 99261886
Effects of growth factors and trefoil peptides on migration and replication in primary oxyntic cultures. May 1999

22/6/21 10121695 99101983
Pregnancy-specific protein B induces release of an alpha chemokine in bovine endometrium. Jan 1999

22/6/22 10103464 98249562
Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Apr 1998

22/6/23 10080018 97304525
The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts. May 1 1997

22/6/24 10064540 99410731
Molecular definition and characterization of recombinant bovine CB8 and CB10: immunogenicity and arthritogenicity. Sep 1999

22/6/25 10031842 99384169
Further pharmacological characterization of bradykinin B1 receptor up-regulation in human umbilical vein. Sep 1999

22/6/26 10026925 99386696
Apolipoprotein E peptide stimulation of rat ovarian theca cell androgen synthesis is mediated by members of the low density lipoprotein receptor superfamily. Sep 1999

22/6/27 09929357 99243390
Characterization of insulin-like growth factor binding proteins (IGFBPs) secreted by bovine adrenocortical cells in primary culture: regulation by insulin-like growth factors (IGFs) and adrenocorticotropin (ACTH).

Feb-Mar 1999

22/6/28 09912281 99201899
Physiological effects and adjuvanticity of recombinant brushtail possum TNF-alpha. Feb 1999

22/6/29 09888791 99214204
Recombinant glycoproteins that inhibit complement activation and also bind the selectin adhesion molecules. Apr 16 1999

22/6/30 09885323 99110008
Mobilisation of healthy donors with lenograstim and transplantation of HLA-genoidentical blood progenitors in 54 patients with hematological malignancies: a pilot study. Dec 1998

22/6/31 09846411 98346492
Expression of biologically active recombinant porcine GM-CSF by baculovirus gene expression system. Jun 1998

22/6/32 09825775 99165172
Recombinant growth differentiation factor-9 (GDF-9) enhances growth and differentiation of cultured early ovarian follicles. Mar 1999

[redacted]3 09823427 99108992
High-level expression of human interleukin-17 in the yeast Pichia pastoris. Dec 1998

22/6/34 09766929 99051018
A less acidic human follicle-stimulating hormone preparation induces tissue-type plasminogen activator enzyme activity earlier than a predominantly acidic analogue in phenobarbital-blocked pro-oestrous rats. Nov 1998

22/6/35 09753419 99101477
Immuno suppressive activities of recombinant glycosylation-inhibiting factor mutants. Jan 1 1999

22/6/36 09716079 99019749
Neurotrimin mediates bifunctional effects on neurite outgrowth via omophilic and heterophilic interactions. Nov 15 1998

22/6/37 09714793 99049872
Macrophage colony-stimulating factor stimulates synthesis and secretion of a mouse homolog of a human IgE-dependent histamine-releasing factor by macrophages in vitro and in vivo. Dec 1 1998

22/6/38 09702972 98409512
[redacted]ombinant human acid alpha-glucosidase: high level production in mouse [redacted]iochemical characteristics, correction of enzyme deficiency in GSDII KO [redacted]. Oct 1998

2/6/39 09698987 98436856
valuation of the contraceptive potential of recombinant human ZP3 and man ZP3 peptides in a primate model: their safety and efficacy. Sep 1998

2/6/40 09623807 98396679
ffect of glycosylated and non- glycosylated prolactin on the proliferation normal human lymphocytes. 1997

2/6/41 09596995 98380992
soluble form of the urokinase plasminogen activator receptor (suPAR) can d to hematopoietic cells. Aug 1998

/6/42 09577725 98315260
osinophil cationic protein/RNase 3 is another RNase A-family onuclease with direct antiviral activity. Jul 15 1998

/6/43 09508659 98216889
ect of administration of a novel recombinant bovine interferon on length estrous cycle in cattle. Jan-Feb 1998

6/44 09483597 98237580
Delayed production of biologically active O- glycosylated forms of human eotaxin by tumor-necrosis-factor-alpha-stimulated dermal fibroblasts. Apr 1 1998

22/6/45 09404058 98095509
Recombinant human tumor necrosis factor and recombinant murine interleukin-1 alter the binding of Escherichia coli to intestine, mucin glycoprotein, and the HT29-C1 intestinal cell line. Nov-Dec 1997

22/6/46 09324773 97455914
Mobilization of CD34+ cells by glycosylated and nonglycosylated G-CSF in healthy volunteers--a comparative study. Sep 1997

22/6/47 09319171 98011519
Effect of active oxygen radicals on protein and carbohydrate moieties of recombinant human erythropoietin. Sep 1997

22/6/48 09317593 98043629
Recombinant soluble interleukin-11 (IL-11) receptor alpha-chain can act as an IL-11 antagonist. Dec 1 1997

22/6/49 09235894 97422554
The glycosylation of IgA produced by murine B cells is altered by Th2 cytokines. Sep 1 1997

22/6/50 09234855 97398469
Regulation of human growth hormone receptor gene transcription by human growth hormone binding protein. Jul 4 1997

22/6/51 09217267 97393072
Recombinant insulin-like growth factor I normalizes expression of renal glucose transporters in diabetic rats. Jul 1997

22/6/52 09096583 97226008
Neuritin: a gene induced by neural activity and neurotrophins that promotes neuritogenesis. Mar 18 1997

22/6/53 09093142 97236424
Nucleotide and corrected amino acid sequence of the functional recombinant rat anaphylatoxin C5a. Mar 20 1997

22/6/54 09073390 97180723
Cycling status of CD34+ cells mobilized into peripheral blood of healthy donors by recombinant human granulocyte colony-stimulating factor. Feb 15 1997

22/6/55 09064831 97164924
Ex vivo neutrophil function in response to three different doses of glycosylated rHuG-CSF (Lenograstim). Jan 1997

22/6/56 09064417 97144419
Conversion of inactive glycosylation inhibiting factor to bioactive derivatives by modification of a SH group. Jan 7 1997

22/6/57 09062170 97149736
Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats. 1997

22/6/58 09051052 97010891
Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion. Oct 1996

22/6/59 09035111 97050602
Regulation of insulin-like growth factor I biosynthesis in porcine granulosa cells. Nov 1996

22/6/60 09012133 97028854
Interaction of reteplase with heparin. A comparison between reteplase and alteplase. Jul 1996

22/6/61 09004664 96336411
A soluble interleukin 6 receptor isolated from conditioned medium of human breast cancer cells is encoded by a differentially spliced mRNA. May 1996

22/6/62 08935106 96428889
Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF. Jul 1996

22/6/63 08908852 97039688
Characterization and determination of the biological activities of noncleavable high molecular weight forms of inhibin A and activin A. Sep 1996

22/6/64 08829433 96373013
Azurocidin, a natural antibiotic from human neutrophils: expression, antimicrobial activity, and secretion. Jun 1996

22/6/65 08793160 96314423
Effects of glycosylated and non- glycosylated G-CSFs, alone and in combination with other cytokines, on the growth of human progenitor cells. Jul-Aug 1996

22/6/66 08756515 96332473
Lack of integrin alpha-chain endoproteolytic cleavage in furin-deficient human colon adenocarcinoma cells LoVo. Aug 1 1996

22/6/67 08733064 96280646
Antithrombin-heparin affinity reduced by fucosylation of carbohydrate at asparagine 155. Jul 9 1996

22/6/68 08711451 96318518
The roles played by the D2 and D3 domains of recombinant human thrombomodulin in its function. Nov 1995

22/6/69 08692635 95301511
The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family [published erratum appears in J Biol Chem 1996 Feb 2;271(5):2874] Jun 16 1995

22/6/70 08683164 95112957
Thrombolytic efficacy of a modified tissue-type plasminogen activator, SUN9216, in the rat middle cerebral artery thrombosis model. Sep 1 1994

22/6/71 08682148 95091831
Effect of cysteine substitutions on the mitogenic activity and stability of recombinant human keratinocyte growth factor. Nov 30 1994

22/6/72 08679844 95045576
Characterisation of neurotrophin dimers and monomers. Nov 1 1994

22/6/73 08676488 94355917
In vivo stimulation of neutrophil function by lenograstim (glycosylated rHuG-CSF) in oncohematologic patients: results of a phase I trial. May 1994

22/6/74 08671210 94245698
Negative feedback regulation of human platelets via autocrine activation of the platelet-derived growth factor alpha-receptor. May 13 1994

22/6/75 08669175 94193692
Recombinant human betacellulin. Molecular structure, biological activities, and receptor interaction. Apr 1 1994

22/6/76 08657609 96118420
Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Jan 1996

22/6/77 08650119 96217265
Factors regulating insulin-like growth factor-binding protein-3 binding, processing, and potentiation of insulin-like growth factor action. Jun 1996

22/6/78 08622353 96146468

The role of the asparagine-linked oligosaccharides of the alpha-subunit in human thyrotropin bioactivity. Feb 1996

22/6/79 08620651 96139496
Proteinase inhibitor 6 cannot be secreted, which suggests it is a new type of cellular serpin. Jan 19 1996

22/6/80 08614914 96134408
Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors. Jan 15 1996

22/6/81 08598099 98039259
Thrombopoietin and the humoral regulation of thrombocytopoiesis [see comments] May 1995

22/6/82 08557991 96363467
Characterization of recombinant heparin cofactor II expressed in insect cells. Dec 1995

22/6/83 08540997 95226607
Insulin-like growth factor (IGF) binding protein 3 in the rat testis: follicle-[illegible]ating hormone dependence of mRNA expression and inhibition of IGF-I [illegible] on cultured Sertoli cells. Feb 1995

22/6/84 08535431 96342889
Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Dec 1995

22/6/85 08470669 96117783
The production of pharmaceutical proteins from the milk of transgenic animals. 1995

22/6/86 08466774 96020506
Glycosylated human recombinant interleukin-1 alpha, neo interleukin-1 alpha, with D-mannose dimer exhibits selective activities in vivo. Aug 1995

22/6/87 08466039 96136631
Identification of pigment epithelium-derived factor in the nterphotoreceptor matrix of bovine eyes [published erratum appears in Protein Expr Purif 1995 Oct;6(5):716] Aug 1995

22/6/88 08456218 96094438
Glycosylphosphatidylinositol -modified murine B7-1 and B7-2 retain costimulator function. Dec 15 1995

22/6/89 08430604 96026183
[illegible]red insulin-induced platelet antiaggregating effect in obesity and in [illegible]e NIDDM patients. Nov 1995

22/6/90 08394130 95337720
nterleukin-13 regulates the phenotype and function of human monocytes. May-Jun 1995

22/6/91 08393591 95324425
enograstim. A review of its pharmacological properties and therapeutic fficacy in neutropenia and related clinical settings. May 1995

22/6/92 08326004 95318875
Relation between structure and anti-viral activity in interferon system] May 995

22/6/93 08325117 95317622
he effects of desferrioxamine and ascorbate on oxidative stress in the eptozotocin diabetic rat. May 1995

22/6/94 08315016 95303027
arbohydrate-dependent biological activities of glycosylated human erferon-beta on human hepatoblastoma cells in vitro. 1995

22/6/95 08292455 95268354
Somatogenic and lactogenic activity of the recombinant 22 kDa isoform of human placental growth hormone. Mar 1995

22/6/96 08243992 95152076
Genomic structure, chromosomal localization, and conserved alternative splice forms of thrombopoietin. Feb 15 1995

22/6/97 08236384 95110840
Structural requirements for dimerization, glycosylation, secretion, and biological function of VPF/VEGF. Jan 5 1995

22/6/98 08210241 94358554
Double-blind randomized phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-beta given intravenously. Apr 1994

22/6/99 08210017 94354808
Expression and characterization of human tissue inhibitor of metalloproteinases-1 in a baculovirus-insect cell system. Aug 30 1994

22/6/100 08193649 95209924
Glycosylation of recombinant human granulocyte colony stimulating factor: implications for stability and potency. 1994

22/7/84 DIALOG(R)File 155:MEDLINE(R) (c) format only 2000 Dialog Corporation. All rts. reserv.
08535431 96342889
Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions.
Lifely MR; Hale C; Boyce S; Keen MJ; Phillips J
Department of Cell Biology, Wellcome Research Laboratories, Beckenham, Cambridge, UK.
Glycobiology (ENGLAND) Dec 1995, 5 (8) p813-22, ISSN 0959-6658 Journal Code: BEL Languages: ENGLISH Document type: JOURNAL ARTICLE
CAMPATH-1H (where CAMPATH is a trade mark of Wellcome group companies), a humanized IgG antibody used in the therapy of lymphoma, leukaemia and rheumatoid arthritis, has been expressed in Chinese hamster ovary, Y0 myeloma and NS0 myeloma cell lines. These engineered cell lines were grown under different culture conditions, and the antibody isolated and purified. N-Linked oligosaccharides, on the CH2 heavy chain region of the antibody, were isolated and analysed by hydrazinolysis, high-performance anion-exchange chromatography with pulsed amperometric detection, laser-desorption mass spectrometry and sequential exoglycosidase treatment. Both the glycosylation pattern and the biological activity of CAMPATH-1H, as measured by antibody-dependent cell-mediated cytotoxicity, were markedly affected by the cell line used to express the antibody. It is concluded that glycosylation of the antibody may be important in the clinical outcome of therapy.

23/6/1 10384687 20177994
Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor. Mar 2000

23/7/2 DIALOG(R)File 155:MEDLINE(R) (c) format only 2000 Dialog Corporation. All rts. reserv.
07694846 94086500
Kinetics of factor Xa inhibition by tissue factor pathway inhibitor.
Huang ZF; Wun TC; Broze GJ Jr
Division of Hematology/Oncology, Jewish Hospital, Washington University Medical Center, St. Louis, Missouri 63110.
Journal of biological chemistry (UNITED STATES) Dec 25 1993, 268 (36) p26950-5, ISSN 0021-9258 Journal Code: HIV Contract/Grant No.: HL-34462, HL, NHLBI Languages: ENGLISH Document type: JOURNAL ARTICLE
Tissue factor pathway inhibitor is a multivalent, Kunitz -type proteinase inhibitor. It directly inhibits factor Xa and, in a factor Xa-dependent fashion, produces feedback inhibition of the factor VIIa/tissue factor catalytic complex which is responsible for the initiation of coagulation. Human recombinant TFPI (rTFPI) produced in Escherichia coli was used to define the kinetic constants describing the human factor Xa:TFPI interaction. The inactivation of factor Xa by E. coli-rTFPI is indistinguishable from that of rTFPI produced in mammalian SK-hepatoma cells, suggesting that post-translational modifications such as glycosylation and phosphorylation do not play a major role in the inhibitory process. The slow, tight-binding inhibition of factor Xa follows the scheme: [formula: see text] Where the enzyme (E) and inhibitor (I) form an initial, immediate collision complex (EI) that then isomerizes slowly to a tightened final EI* complex. In the absence of other additions, the initial Ki (=k2/k1) and final Ki* for the inhibition of factor Xa by E. coli-rTFPI are 1.24 nM and 26.4 pM, respectively. In the presence of calcium ions (5 mM) the interaction between factor Xa and rTFPI is substantially weaker, with a Ki of 42.7 nM and Ki* of 85.2 pM. The addition of other components of the prothrombinase complex produces enhanced factor Xa inhibition predominantly through an effect on the initial Ki. In the presence of calcium ions and saturating concentrations of phospholipids and factor Va, the Ki and Ki* for factor Xa inactivation are 2.04 nM and 52.3 pM. The enhancing effect of heparin on the inhibitory process is concentration dependent and exhibits an optimum, reminiscent of the "template" model for heparin's acceleration of thrombin and factor Ixa inhibition by antithrombin III. At optimal concentrations, the major mechanism of heparin action is also a reduction in the Ki of the initial encounter complex between factor Xa and rTFPI.

24/6/1 10512164 20405164
Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabete Insuline Orale group [see comments] Aug 12 2000

24/6/2 10472170 20262971
Subcutaneous administration of recombinant glycosylated interleukin 6 in patients with cancer: pharmacokinetics, pharmacodynamics and immunomodulatory effects. Apr 2000

24/6/3 10429829 20263631
O- glycosylation delays the clearance of human IGF-binding protein-6 from the circulation. May 2000

24/6/4 10367142 20209710
Efficacy of a new formulation of lenograstim (recombinant glycosylated human granulocyte colony-stimulating factor) containing gelatin for the treatment of neutropenia after consolidation chemotherapy in patients with acute myeloid leukemia. Feb 2000

24/6/5 10342599 20179503
Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation. Mar 2000

24/6/6 10333780 20188558
Lenograstim-mobilized peripheral blood progenitor cells in volunteer donors: an open label randomized split dose escalating study. Feb 2000

24/6/7 10075654 97217420

Production and characterization of recombinant active mouse gelatinase B from eukaryotic cells and in vivo effects after intravenous administration. Feb 15 1997

24/6/8 10043890 99399205
Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2). Jul-Aug 1999

24/6/9 09986592 99347110
A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Lenograstim/Breast Cancer Study Group. Jun 1999

24/6/10 09910060 99136861
Glycosylated and non- glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF)--what is the difference? Dec 1998

24/6/11 09839230 99164131
A phase II double-blind randomized study of the simultaneous administration of recombinant human interleukin-6 and recombinant human granulocyte colony-stimulating factor following paclitaxel and carboplatin [illegible]herapy in patients with advanced epithelial ovarian cancer. Mar 1999

24/6/12 09777218 99111434
Characterization of recombinant type II collagen: arthritogenicity and tolerogenicity in DBA/1 mice. Dec 1998

24/6/13 09594289 98307491
Flow cytometry comparison of CD34+ subsets in bone marrow and peripheral blood after priming with glycosylated or non- glycosylated rhG-CSF [letter] Jun 1998

24/6/14 09549536 98314668
Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus [see comments] Oct 25 1997

24/6/15 09296842 97441094
A European phase II study of recombinant human granulocyte colony-stimulating factor (lenograstim) in the treatment of severe chronic neutropenia in children. Lenograstim Study Group. Sep 1997

24/6/16 09193165 97364416
Pharmacokinetic studies of intravenous glycosylated recombinant human granulocyte colony-stimulating factor in various hematological disorders: [illegible]e correlation between the half-life and bone marrow myeloid cell pool. [illegible]7

24/6/17 08976005 97181616
Characterization of canine herpesvirus glycoprotein C expressed by a recombinant baculovirus in insect cells. Dec 1996

24/6/18 08935106 96428889
Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF. Jul 1996

24/6/19 08751047 96265676
Severe hypoglycemia in insulin-dependent diabetic children treated by multiple injection insulin regimen. Mar 1996

24/6/20 08712080 96366672
Clinical studies with the new glycosylated recombinant prourokinase. Nov-Dec 1995

24/6/21 08683164 95112957
Thrombolytic efficacy of a modified tissue-type plasminogen activator, N9216, in the rat middle cerebral artery thrombosis model. Sep 1 1994

24/6/22 08678349 95015468
New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction. Prourokinase Study Group. Nov 1 1994

24/6/23 08657609 96118420
Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Jan 1996

24/6/24 08585752 96027660
Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma. Oct 1995

24/6/25 08536459 96114549
The effects of repeated daily recombinant human insulin-like growth factor I administration in adolescents with type 1 diabetes. Oct 1995

24/6/26 08519242 96262845
A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma. Dec 1995

24/6/27 08448624 96110370
Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen. May 1995

24/6/28 08448622 96110368
Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices. May 1995

24/6/29 08392048 95280977
A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group [see comments] Jun 22 1995

24/6/30 08346579 95349118
Effect of growth hormone treatment on glucose tolerance in a patient with cystinosis after kidney transplantation. May-Jun 1995

24/6/31 08329442 95323952
An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models. May 1995

24/6/32 08210241 94358554
Double-blind randomized phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-beta given intravenously. Apr 1994

24/6/33 08191970 95136886
Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia. Nov 1994

24/6/34 08174157 95209927
The optimal dose of glycosylated recombinant human granulocyte colony stimulating factor for use in clinical practice: a review. 1994

24/6/35 08162234 94264694
Manipulation of renal disposition of human recombinant superoxide dismutase by chemical modification. Feb 1994

24/6/36 07990576 94351937
Recombinant human non- glycosylated granulocyte-macrophage colony-stimulating factor in allogeneic bone marrow transplantation: double-blind placebo-controlled phase III clinical trial. Aug 1994

24/6/37 07781354 93250589
Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. Apr 1993

24/6/38 07757942 93160993
Low-dose non- glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantation. Jan 1993

24/6/39 07720695 94134605
Interleukin-2-containing liposomes: interaction of interleukin-2 with liposomal bilayers and preliminary studies on application in cancer vaccines. Dec 1993

24/6/40 07578374 93314522
Comparison of morning or bedtime insulin with and without glyburide in secondary sulfonylurea failure. Jun 1993

24/6/41 07500300 93170458
Comparative pharmacokinetics of single-dose administration of mammalian and bacterially-derived recombinant human granulocyte-macrophage colony-stimulating factor. Jan 1993

24/6/42 07380226 92154141
Recombinant human GM-CSF: present clinical results and potential use in oncologic and hematologic disorders. 1991

24/6/43 07375477 92084267
Recombinant human granulocyte macrophage colony stimulating factor following alternating non cross resistant chemotherapy in Hodgkin's disease. Nov-Dec 1991

24/6/44 07340714 90276975
Heterogeneity of circulating hematopoietic progenitors in cancer patients treated with high-dose cyclophosphamide and recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF). Jan-Feb 1990

24/6/45 07338478 90237829
Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non- Hodgkin's lymphoma [see comments] May 1990

24/6/46 07296691 93217664
A randomised vehicle controlled multicenter dose finding phase. II. Study of glycosylated rhuG-CSF in 121 patients after bone marrow transplantation. 1992

24/6/47 07216350 93170102
Morning or bed-time insulin with or without glibenclamide in elderly type 2 diabetic patients unresponsive to oral antidiabetic agents. Dec 1992

24/6/48 07138512 93022819
Prolongation by differentiation-stimulating factor/leukemia inhibitory factor of the survival time of mice implanted with mouse myeloid leukemia cells. Oct 1992

24/6/49 07033673 92256551
A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative Group [published erratum appears in Ann Hematol 1992 Jun;64(6):312] Apr 1992

24/6/50 06986287 92114147
Induction of an organ-specific autoimmune disease, lymphocytic hypophysitis, in hamsters by recombinant rubella virus glycoprotein and prevention of disease by neonatal thymectomy. Feb 1992

24/6/51 06975388 92015776
[Hematological effect of 14 days treatment of recombinant human granulocyte colony-stimulating factor for neutropenia in myelodysplastic syndromes] Jul 1991

24/6/52
06966977 91190693

Placebo controlled phase I/II study of subcutaneous GM-CSF in patients with germ cell tumors undergoing chemotherapy. Nov 1990

24/6/53 06958255 90349569
Priming of CD4+ T cells specific for conserved regions of human immunodeficiency virus glycoprotein gp120 in humans immunized with a recombinant envelope protein. Aug 1990

24/6/54 06955566 90274441
[Clinical effect of recombinant human granulocyte colony-stimulating factor in bone marrow transplantation. The Japan rhG-CSF Clinical Study Group] Jun 1990

24/6/55 06897905 91183827
Comparison of basal and prandial insulin therapy in patients with secondary failure of sulphonylurea therapy. Jan 1991

24/6/56 06873383 92183543
Split-mixed insulin regimen with human ultralente before supper and NPH (isophane) before breakfast in children and adolescents with IDDM. Nov 1991

24/6/57 06834835 92090115
[redacted]arative pharmacokinetics and pharmacodynamics of epoetin alfa and [redacted]i beta. Dec 1991

24/6/58 06643632 90157774
Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF [see comments] Feb 24 1990

24/6/59 06610706 90305379
The variability of the absorption of subcutaneously injected insulin: effect of injection technique and relation with brittleness. Jul 1990

24/6/60 06562781 91193873
The pharmacokinetic pattern of glycosylated human recombinant lymphotoxin (LT) in rats after intravenous administration. Sep 1990

24/6/61 06068988 88148716
Efficacy of recombinant human granulocyte-macrophage colony-stimulating factor in rhesus monkeys. 1987

24/6/62 06007113 89119963
A randomized trial of the efficacy and acceptability of a pen injector. Nov 1988

24/6/63 05883222 89053215
Human proinsulin. Does it improve the treatment of type I diabetics? 1988

[redacted]4 05750718 89337443
[redacted]mparison of human ultralente- and lente-based twice-daily injection regimens. Aug 1989

24/6/65 05691641 89376421
Comparison of fixed-ratio versus variable-ratio regular and NPH semisynthetic human insulin in insulin-requiring diabetic patients. Jul-Aug 1989

24/6/66 05202833 87242927
Recombinant human GM-CSF induces leukocytosis and activates peripheral blood polymorphonuclear neutrophils in nonhuman primates. Jul 1987

24/7/58 DIALOG(R)File 155:MEDLINE(R) (c) format only 2000
Dialog Corporation. All rts. reserv.
06643632 90157774
Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF [see comments]
Gribben JG; Devereux S; Thomas NS; Keim M; Jones HM; Oldstone AH; Linch DC
Department of Haematology, Faculty of Clinical Sciences, University College and Middlesex School of Medicine, London, UK.

Lancet (ENGLAND) Feb 24 1990, 335 (8687) p434-7, ISSN 0140-6736 Journal Code: L0S Comment in Lancet 1990 May 19;335(8699):1217
Languages: ENGLISH Document type: CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; JOURNAL ARTICLE
In 4 out of 16 patients receiving recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) in phase I/II studies antibodies developed to the recombinant protein. The antibodies react with sites on the native protein backbone which are normally protected by O-linked glycosylation but which are exposed in rhGM-CSF produced in yeast and Escherichia coli. Antigenicity of recombinant human proteins due to non glycosylation may have relevance to the choice of host system for production of factors for clinical use.

US 094416540DP1



Creation date: 10-23-2003
Indexing Officer: TGEBRYESUS - TSIGEREDA GEBRYESUS
Team: OIPEBackFileIndexing
Dossier: 09441654

Legal Date: 04-24-2001

No.	Doccode	Number of pages
1	CTNF	6
2	892	1
3	FOR	65
4	NPL	6
5	NPL	4
6	NPL	4
7	NPL	9

Total number of pages: 95

Remarks:

Order of re-scan issued on .....